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Abstract 
 
Past research in oscillatory baffled reactors has shown that there are significant 
technological and business advantages in using such reactor technology in fine chemical 
and pharmaceutical industries: shorter reaction times, fewer by-products, uniform 
product quality and higher yields, while at the same time with a significant saving in 
space, capital and running costs. 
 
This project focused on the robustness and adaptability of the continuous 
oscillatory baffled reactor (COBR) for a large spectrum of chemical reactions that are 
performed in very different fields of industry: from cosmetics and fine chemicals to 
pharmaceutical products. In particular, the emphasis was on cross contamination issues 
which may occur when different reactions are performed in a tandem fashion in this 
reactor.  
 
The experimental results indicate that the COBR is well suited to a broad 
spectrum of chemical reactions, as well as for crystallization operations. During the 
continuous production of a fine chemical and two active pharmaceutical ingredients in 
tandem the conditions inside the reactor remained stable and were easily controlled. The 
minimal amounts of contaminants present and the high quality of the products obtained 
are a testament to the consistent operation and robust nature of the COBR. 
 
The three production phases were interspersed with a well-defined cleaning 
procedure. The established cleaning protocol is simple, efficient and fast, while the 
amount of waste generated is minimized. The cleaning kinetics is of first order, which is 
consistent with previous work. 
 
The results reported in this thesis show that the COBR, which incorporates 
quality-by-design principles, is a suitable alternative to current mixing technologies and 
can be readily assimilated into a variety of fine chemical and pharmaceutical 
manufacturing processes. 
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CHAPTER 1  
INTRODUCTION 
 
  
A good engineer is a person who makes a design  
that works with as few original ideas as possible.  
 
Freeman Dyson, theoretical physicist and mathematician 
 
 
1.1 - Mixing technology, OBR and COBR 
 
Fine chemicals and drugs manufacturing has long been associated with batch 
processing because production runs are segregated into lots, making it relatively easy to 
pinpoint out of specification product. In addition, laboratory scale experiments on new 
pharmaceutical compounds  are often done in batch and the shortest way of migrating a 
process to full-scale is to mimic what happens at a small-scale (Kossik 2002; Jr. and 
Lodaya 2004; Swichtenberg 2008). The mindset of pharmaceutical companies is then 
geared towards batch-wise production, even if it compromises quality and yield, whilst  
increasing downstream purification units with associated wastes as well as processing 
time of pharmaceutical products (Plumb 2005; TL LaPorte 2007).  
 
The drive towards implementing innovative continuous manufacturing 
technologies in the pharmaceutical production environment has gathered significant 
momentum recently. A recent report by AstraZeneca showed that crystallisation of an 
active pharmaceutical ingredient (API) for one of its best selling drugs was done in 12 
minutes in a continuous crystallizer in comparison of 9 hours and 40 minutes in a 
traditional batch stirred tank crystallizer of 6.5 m3 to achieve the same solid 
concentration with better specifications, e.g. filterability (Lawton et al 2009). This 
example has offered a paradigm shift to the long-established batch manufacturing 
processes. In fact, there are several drivers making the use of continuous reactors more 
appealing than its batch counterpart, such as minimizing the footprint and chemicals 
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inventory in newly built plants while maintaining the production volume flexibility that 
a continuous process is able to deliver, therefore keeping initial investment and 
production costs down (Jr. and Lodaya 2004; Pellek and Arnum 2008; Thakore and 
Bhatt 2008). 
 
   In terms of retro-fit, i.e. just to replace batch stirred tank crystallizers by 
continuous crystallizers in existing plants, this allows for better and greater control on 
product quality and eliminates in some cases the need for milling processes. In the 
AstraZeneca case, this represented an estimated 50% reduction in capital costs, and 
further avoidance of  >£300k per annum costs in personnel, milling losses and other 
inefficiencies (Lawton, Steele et al 2009). Continuous processing minimizes the 
downtime associated with batch operations, can run continuously for either a short or a 
long period of time depending on the throughput (T/yr) required. The operational 
conditions are monitored and controlled continuously along the length of the continuous 
reactor/crystallizer. In fact, continuous reactor technologies offer a more simple, 
predictable and controllable solution for pharmaceutical manufacturers together with 
using less energy and solvents, while minimizing the production of waste (Liu, Lipták et 
al 1997; Angelucci 1999; Vervaet and Remon 2005; Crosby 2006).  
 
In addition to this, regulatory bodies have recently published guidelines with the 
purpose of making manufacturers to fully understand and optimize the way their 
pharmaceutical products are developed, evaluated and manufactured, such as the 
Critical Path Initiative (CPI) issued by the FDA or the Q8 guideline published by the 
International Conference on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH), which focuses on Quality by Design (QbD) 
(Plumb 2005; Pellek and Arnum 2008; Swichtenberg 2008). These regulatory efforts 
present the perfect opportunity for continuous process technology to be embraced and to 
be successfully implemented. One example is that of Genzyme’s manufacturing 
process, which utilizes continuous reactors that have been approved by FDA and been 
running since 2007 (Ni 2009).  
 
One of the important aspects of both CPI and QbD is the prevention of cross-
contamination. The design of modern pharmaceutical equipment has to take into 
account that there is a current trend for new drugs to be tailored for narrower population 
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targets and so manufactured in smaller production runs (Gassmann et al 2004; Voelter-
Mahlknecht and Mahlknecht 2004). In order to maximize the plant productivity it is 
then a requirement to use the same parts, such as chemical reactors, to manufacture 
different products. In this case avoiding cross-contamination is of critical importance. 
The cleaning of a continuous reactors utilizes a single-path cleaning-in-place (CIP) 
procedure that does not require cleaning to be done in contact with the outside 
environment, which reduces process downtime, waste, risk of cross-contamination and 
brings operational costs down (Perka et al 1993; Gambrill 1995; Chew, Tonneijk et al 
2006).  
 
One successful development in the continuous process technology design is the 
Continuous Oscillatory Baffled Reactor (COBR). The COBR is a reaction/mixing 
device and consists of a glass or stainless steel tube with periodically spaced circular 
orifice baffles within, perpendicularly orientated in relation to the flow. The fluid inside 
the tube is mixed by means of oscillatory movement, caused by a motor placed at one or 
both ends of the reactor. 
 
 Coupling a baffled tube with oscillatory movement results in excellent mixing of 
fluids. When a fluid that is being oscillated at a reasonable velocity encounters a sharp 
barrier, disruption of the flow occurs and eddies around the annular baffles are formed: 
as illustrated in Figure 1.1, a doughnut-shaped vortex is produced downstream of each 
baffle pulling the fluid to the tube wall when the oscillatory cycle begins and when the 
direction of flow is reversed the vortex is pushed back in to the centre of the tube, while 
a new vortex is formed on the other side of each baffle (Brunold et al 1989; Gelicourt 
2000). This continuous generation and cessation of eddies provides a vigorous axial and 
radial mixing within each baffled region defined by two adjacent baffles, which can be 
considered as a perfectly mixed continuous stirred-tank reactor (CSTR) (Mackley and 
Ni 1991; Nelson 2001). As a consequence, the entire COBR behaves as a series of 
perfectly mixed CSTRs – very sharp residence time distribution measurements are 
achieved using this technology (Ni 1995; Ni and Pereira 2000; Ni et al 2003). 
 
 There are two designations that are frequently used throughout this thesis: OBR 
(oscillatory baffled reactor) and COBR. The former refers to batch operation, while the 
latter to continuous operation, as suggested by the name. 
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Figure 1.1 Flow pattern in an OBR operating with oscillation;  
a) down stroke, b) up stroke 
 
 
The characteristic oscillatory flow of an OBR is defined by two dimensionless 
groups, the oscillatory Reynolds number (Reo) and the Strouhal number (St) (Brunold et 
al 1989): 
 
µ
ωρ 0Re
Dx
o =            
 (1.1)   
 
04
t
x
DS
π
=  
      (1.2) 
  
 When dealing with the flow in a COBR, the net flow Reynolds number is also 
pertinent dimensionless group: 
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µ
ρuD
n =Re  
(1.3) 
 
 
where ρ is the density of the bulk fluid (kg.m-3), D is the OBR diameter (m), x0 the 
centre-to-peak oscillation amplitude (m), ω the angular oscillation frequency (rad.s-1), µ 
dynamic viscosity (N.s.m-2) and u the superficial net flow velocity (m.s-1). 
 
 
 
1.2 - Motivation and Structure of the Project 
 
 It is believed that a central role in the adoption of a new technology by its 
potential users is that research done behind closed doors needs to be published to be 
legitimized (Technologies 2008; Thomas 2008). In this way, proactive companies that 
are prepared to adopt a proven, yet emerging technology earlier than their rivals can 
gain a competitive advantage. Examples can be found in diverse technology intensive 
businesses. For example, the introduction of a rear wing in the 1968 Lotus 49 in 
Formula 1 proved to be so competitive that by the end of that year most other cars were 
updated in a similar fashion; the Apple Macintosh 128K was such a commercial success 
due to its use of a graphical user interface (GUI) that Microsoft applied the same 
interface principles in its Windows package as a GUI for its own MS-DOS operating 
system (Scarso 1996; Rios 2007).  
 
Having proved that the OBR and COBR design is a better alternative to 
conventional reactors in a number of diverse applications such as heat and mass transfer 
(Hewgill et al 1993; Mackley and Ni 1993; Mackley and Stonestreet 1995), 
polymerization (Ni et al 1999; Ni et al 2003), fermentation (Gaidani et al 2005; 
Masngut et al 2006), crystallization (Ni et al 2004; Caldeira and Ni 2009; Ni and Liao 
2010), biodiesel production (Harvey et al 2003) or fine chemicals (Winder 2003; Ni 
2006), the time has arrived to demonstrate that this relatively young technology is also 
suitable for extended pharmaceuticals and fine chemicals syntheses, in order to establish 
the robustness, versatility and adaptability of COBR – not only several chemical 
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reactions will be studied using this reactor technology, but also will these be done in a 
sequential fashion, with cleaning procedures in between. Each product must meet the 
stringent quality standards set by regulatory agencies. The synthesis of different 
products in tandem also allows for the degree of cross-contamination in the 
manufacturing process to be assessed, and the efficiency and kinetics of the cleaning to 
be evaluated.   
  
The structure of this thesis is as follows: after the introduction in Chapter 1, the 
literature survey is given in Chapter 2, covering the oscillatory baffled reactors, fouling 
encrustation and cross-contamination, cleaning approaches, quality by design, the 
relevant regulatory matters in the chemical and pharmaceutical industries and 
acceptable limits of cross-contamination. The experimental setup, materials used and 
analytical techniques are presented in Chapter 3, and the chemistry screening together 
with a brief introduction for each of the chemical reactions performed is described in 
Chapter 4. Chapter 5 is dedicated to the results and discussion of the production 
campaigns performed in the COBR for the selected chemistries. Conclusions and 
suggestions for future work to be carried out are outlined in Chapter 6. 
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CHAPTER 2  
LITERATURE REVIEW 
 
 
 
Learning and innovation go hand in hand. The arrogance of success is to                           
think that what you did yesterday will be sufficient for tomorrow.  
 
William Pollard, physicist and priest 
 
 
 
 This chapter presents literature studies covering the fields of the oscillatory 
baffled reactors, fouling and encrustation, cleaning methods and strategies, the relevant 
regulations to which the chemical and pharmaceutical industries must abide to in order 
to market up-to-standard products as well as the levels of cross-contamination 
acceptable in a finished product. 
 
 
2.1- OBR and COBR 
 
The origins of oscillatory flow can be traced to Van Dijck’s patent on a 
reciprocating plate column (RPC) as a means to improve extraction or washing 
processes by bringing into close contact two immiscible or slightly miscible liquids 
(Dijck 1935). One of his original drawings is shown in Figure 2.1. 
 
According to the classification put forward by Lema and co-workers (2001) 
there are two types of oscillatory flow reactors concerning the way in which the 
contents inside are forced into motion: reactors in which the movement is provoked by 
the cyclic introduction of feed via a pump (plug or membrane) and reactors in which the 
oscillation is created via the characteristic cyclic motion of a part of the reactor. Both 
the RPC and OBR/COBR belong to the latter group - in RPCs and laboratory scale 
batch OBRs, oscillatory flow movement is created by the cyclic movement of the plates 
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and annular baffles; in COBRs and some batch OBRs it is the oscillation piston 
connected to one or both ends of the reactor that creates the oscillatory movement 
(Dijck 1935; Mackley and Ni 1991). 
 
Since Van Dijck’s pioneering work hundreds of scientific papers have been 
published in this research field, but it was not until the last two decades that the research 
on oscillatory flow mixing and its application in the chemical industry has grown 
substantially and there has been a constant stream of research papers published in this 
area since the early 1990’s, as is illustrated in Figure 2.2.  
 
 
Figure 2.1 Scheme of Van Dick’s reciprocating plate column 
9 
 
 
Figure 2.2 Number of publications containing the words “oscillatory” and “baffled”, 
according to ISI Web of Knowledge (www.isiknowledge.com) 
 
 
2.1.1 – OBR 
 
A review of the several studies carried out in OBR is presented in the following 
sections. Fundamental research in oscillatory flow in a baffled tube has been carried out 
covering flow patterns, mixing, the effect of several OBR geometrical parameters on 
mixing (e.g. baffle orifice diameter, baffle spacing, baffle thickness, reactor diameter), 
the effect of oscillation frequency and amplitude on mixing, heat and mass transfer 
characteristics, residence time distribution and turbulent properties, which include both 
experimental and numerical studies. These scientific publications set the basis for this 
further study in both batch OBR and COBR, regarding their applicability and suitability 
to a number of different chemical reactions and processes. 
 
 
  2.1.1.a – Flow characteristics 
 
Brunold et al  (1989) first reported that large scale eddy mixing can be generated 
in regions between sharp edges present in rectangular or cylindrical cross-section ducts 
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when oscillatory flow was introduced. A year later Howes and Mackley (1990) 
observed axial dispersion in a series of tracer experiments and concluded that the OBR 
was able to operate at near plug-flow conditions. Ni and Gelicourt (2002) found that the 
axial dispersion increased with the density of the solution when they studied the axial 
dispersion in a baffled column with 50 mm diameter. Both axial and radial dispersion 
were characterized in a batch OBR using the Laser Induced Fluorescence technique 
(Fitch and Ni 2003). Electrical Impedance Tomography was used for on-line 
measurements and the analysis of the dispersion enabled the description and prediction 
of the characteristics of the oil-water emulsion present in an OBR (Vilar et al 2008). 
 
Gao and colleagues used the Particle Imaging Velocimetry (PIV) technique to 
determine local velocity components and found that complete mixing was consistently 
achieved under low oscillatory Reynolds numbers (Gao et al 2002). PIV was also used 
by Fitch and co-workers (2005) in conjuction with computational fluid dynamic to 
study the mixing effects of fluid viscosity in an OBR  and concluded that good mixing 
was achieved in the OBR if the ratio between the plane-averaged axial and radial 
velocities was lower than 3.5.  
 
 
2.1.1.b – Geometrical parameters and operating conditions 
 
Eddy formation and the impact of the OBR geometrical parameters on these 
characteristics was first studied by Knott and Mackley (1980) and followed by Brunold 
et al (1989). Both studies reported that the cycle of eddies formation and disruption was 
optimal for a baffle spacing of 60% in a tube with an internal diameter of 25 mm. Since 
then a multitude of other studies investigated the impact of the baffle free area (α), 
baffle spacing (L), baffle thickness (δ), and of the frequency (f) and amplitude (x) of 
oscillation on mixing efficiency. Those geometric parameters are shown in Figure 2.3. 
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Figure 2.3 Schematic representation 
of an OBR. di – reactor internal 
diameter, δ – baffle thickness, L – 
baffles spacing, d0 – orifice diameter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The influence of the baffle free area (α), defined as d02/di2, on mixing time was 
evaluated by Brunold et al (1989). They reported that α should be 34% in order for 
optimal mixing to occur. Later on, Ni et al (1998) varied α from 11 to 51% and found 
that a ratio of 20-22% was the optimum. As a result, a ratio of 21% was used in the 
experimental work for this project.  
 
The ideal baffle spacing (L) is the one that allows the generated eddies to fully 
develop in between the baffles, whilst at the same time creating the conditions for good 
mixing to occur. In other words, if L is too small the formation of eddies in the inter-
baffle space due to the oscillatory motion of the flow is severely disturbed; however, if 
L is too big, eddies formed won’t be able to cover the inter-baffle space in its entirety 
thereby rendering mixing less efficient. While Brunold et al (1989) suggested that L 
should be 1.5d, Ni and Gao (1996)  recommended that L should be 1.8d for better 
mixing. 
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Another important parameter in the design of an OBR is the baffle thickness (δ). 
If the baffles are too thick and eddies remain on the edges of the baffles for too long, the 
formation of vortex can be compromised. These findings were corroborated by Ni et al 
(1998) who suggested that thinner baffles helped reducing mixing times. Ni and 
Stevenson (1999) also reported that the existence of a gap between the outer baffle and 
the inner tube diameter affected the mixing patterns and resulted in a lengthening of 
mixing time in an OBR. 
 
The operational parameters of the OBR, e.g. frequency (f) and amplitude (x0), 
have a decisive input on the way in which fluid behaves inside the OBR, for example, 
on controlling both droplet and particle sizes in suspension polymerization of 
acrylamide and methylmethacrylate (Gough, Ni et al 1997; Ni et al 1998; Ni et al 1999; 
Ni et al 2001; Ni et al 2003). The impact of f and x0 on backmixing was also studied by 
Takriff and Masyithah (2002) and later by Reis and co-workers (Reis et al 2004; Reis et 
al 2010), who demonstrated that the oscillation, with a particular relevance to x0 
affected the backmixing phenomena due to the variation in mixing length.  
 
 
2.1.1.c – Heat and mass transfer 
 
Heat and mass transfer characteristics of the OBR were the subject of study by 
different researchers. Stephens and Mackley (2002) used two different OBR 
configurations – one where annular baffles were oscillated within the tube and other 
where oscillatory motion was applied to the fluid in a tube with fixed annular baffles – 
and demonstrated that the heat transfer coefficient depended on the intensity of 
oscillation. Zhang et al (2005) also showed the significance of frequency and amplitude 
with regards to heat transfer, and concluded that an increase in oscillatory velocity led 
to an enhancement of heat transfer in the OBR. 
 
The effect that periodic oscillatory motion inside a baffled tube has on mass 
transfer of oxygen into water was discussed by Hewgill and co-workers (1993). They 
found that the volumetric oxygen transfer coefficient offered a 6-fold increase when a 
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tube was set up in the presence of both baffles and fluid oscillation. In a comparison 
between the performance of an OBR and a STR in a yeast re-suspension operation made 
by Ni et al (1995), it was concluded that the volumetric oxygen transfer coefficient was 
75% higher in the OBR than that in a conventional STR.  
 
 
2.1.1.d – Numerical and simulation studies in OBR  
 
Howes (1988) first studied the dispersion of unsteady flow in baffled tubes using 
a numerical code. This work was later further developed by Roberts (1992) into the 
study of the flow in 2-D baffled channels. 
 
Computational fluid dynamics (CFD) has been used extensively in recent times 
in order to get a better insight into the flow characteristics in the OBR. Examples of this 
are the published work by Ni et al (2002) and by Chew et al (2004). In the former, CFD 
was used to generate a 3-D numerical simulation of the flow in a batch OBR, which 
were in good agreement with laboratory experiments. In the later study, the flow 
patterns of both OBR and STR are compared using CFD and the spatial and temporal 
distribution analysis showed that the OBR is an attractive mixing technology alternative 
for process intensification. The effect of viscosity on mixing performance in a batch 
OBR was investigated by Fitch et al (2005) using CFD together with Digital Particle 
Image Velocimetry (DPIV) in order to provide guidance notes for future industrial 
applications of this mixing technology when dealing with viscous fluids. 
 
Mathematical models were also developed by Hounslow and Ni (2004) in which 
the coalescence and breakage of methylmethacrylate droplets were modelled and results 
compared agreeably with experimental data. Zhang and co-workers similarly developed 
a mathematical model with the objective of optimizing the heat transfer in the OBR 
(Zhang et al 2005). 
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2.1.1.e – Applications 
 
The fundamental research on batch OBRs was complemented with studies on 
the applicability of this novel mixing technology, namely with regards to chemical 
reactions, energy efficiency, polymerization, crystallization, fermentation, mass and 
heat transfer, product engineering and process intensification. 
 
 Ni and Mackley (1993) followed a simple chemical reaction in the batch OBR 
and STR and found that the former was much more energy-efficient alternative. Later 
Ni et al (2001) compared the flocculation of bentonite and of a bacterial species using 
the same type of reactors.  A similar level of flocculation was obtained in the OBR with 
much lower strain rate, when compared with a STR.  
 
In suspension polymerization,  Ni et al (1999; 2003) reported that by changing 
both the amplitude and frequency of the oscillation, they were able to control the size 
and shape of the polymers synthesized. These conclusions were later confirmed for the 
inverse phase suspension polymerisation of acrylamide (Ni et al 2003). 
 
More recently, Gaidhani et al (2005) used the batch OBR in the production of 
pullulan (a polysaccharide polymer) and compared the microbial growth rates in the 
OBR and the STR. The results showed that the growth rate was much faster in the batch 
OBR due to the enhanced mass transfer rate. These results were later supported by 
Masngut et al (2006), who investigated solvent fermentation from palm oil mill effluent, 
cell growth, glucose consumption and solvent production. 
 
Ni and Liao (2008) studied the crystallization of L-glutamic acid and found that 
the metastable zone width was narrower in the OBR than that in the STR, due to the 
more uniform mixing and better heat transfer characteristics. Following from this work, 
the effects of mixing, crystal seeding and baffle material on the crystallization of L-
glutamic were examined, and by finely controlling OBR parameters the desired crystal 
polymorph were obtained (Ni and Liao 2010). The OBR performed well against the 
STR in a protein refolding operation due to its superior mixing and linear scale-up 
characteristics (Mackley et al 2001).    
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2.1.2 - COBR 
    
The expansion of the OBR is the COBR, which follows the same principles but 
works in a continuous fashion. This section reviews the fundamental research for the 
COBR, as well as some of its applications. 
  
 
 2.1.2.a – Residence time distribution (RTD) 
 
Dickens et al (1989) examined the RTD profiles of a COBR and near plug-flow 
characteristics were achieved, with similar magnitudes of axial and radial velocities. 
Similar results were observed by Mackley and Ni (1991) and by Ni (1994). With the aid 
of a thin beam of light reflecting from small particles suspended in the fluid, Baird and 
Rao (1995) were able to observe well defined flow patterns. Particle velocities inside a 
COBR were measured by Liu et al (1995) and it was shown that narrower RTDs are 
achievable for particles with a density distribution. Ni and Pereira (2000) confirmed 
earlier results obtained by Mackley et al (1996), affirming that plug-flow behaviours 
dominated in the COBR for a range of laminar-flow net Reynolds numbers. 
 
The breakage of oil droplets dispersed in water was studied by Mignard et al 
(2004) using a high speed camera and the impact of frequency and amplitude of 
oscillation in a COBR was investigated. Studies regarding mean size distribution of 
droplets in a COBR were carried out by Pereira and Ni (2001) and it was found that 
frequency and amplitude of oscillation were more important than the net flow in 
shaping the mean size distribution of the droplets. 
 
 
  2.1.2.b – Heat and mass transfer 
 
Mackley et al (1990) reported that when a net flow was superimposed with 
oscillatory motion in a baffled tube a significant increase of the convective heat transfer 
coefficient was observed. Mackley and Stonestreet (1995) also performed heat transfer 
experiments where they remarked that under certain oscillation conditions a 30-fold 
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increase in the Nusselt number, the ratio between convective and conductive heat 
transfer, was observed under low net flow Reynolds numbers.  
 
 
 2.1.2.c – Scale-up/down 
 
 The versatility of this mixing technology was illustrated by Harvey et al (2003) 
when a scaled-down version of the design was studied and the good mixing and particle 
suspension characteristics found in bigger versions were retained. These results are 
particularly interesting for speciality chemicals production and high-throughput 
screening. Reis et al (2004) confirmed the same oscillatory flow mixing principles of 
the COBR using a mini screening reactor (total volume = 4.5 ml). In a series of 
experiments using 3 different sets of baffled tubes (from 1 to 4.5 m long and 24 to 150 
mm of internal diameter) working either in batch or continuous, Smith and Mackley 
(2006) showed that mixing intensity was largely independent of the internal diameter of 
the tubes, thus making this type of reactor technology easy to scale up linearly, from 
laboratory scale to pilot-plant and up to full industrial size. 
 
 
  2.1.2.d - Applications 
 
The fundamental research on the COBR created a knowledge base for exploring 
applications. One of the first examples was in wastewater treatment area. The treatment 
of organic matter in aqueous solution was achieved using a photo-oxidation reactor, 
whereby the excellent gas-liquid mixing kept the solid catalyst-coated particles in 
suspension (Harvey and Stonestreet 2001). In a saponification reaction for the  
continuous production of sterols using the COBR mixing technology, an eight-fold 
reduction of reaction time and a 100-fold footprint minimization were achieved when 
comparing with a full-scale batch reactor, maintaining the same production rates and the 
quality of the batch operaton (Harvey et al 2001). A significant reduction of residence 
time was also achieved in biodiesel production, thereby intensifying the existing process 
(Harvey et al 2003). Using a COBR micro-bioreactor, Reis et al (2006) reported a 50% 
decrease in residence time in the production of γ-decalactone, when compared to the 
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STR. This result was accomplished due to the enhanced mass transfer capabilities 
through the increase of the interfacial area between the two immiscible liquid phases 
involved in this process. 
 
In the production of a speciality chemical product the existing two STRs were 
replaced by a COBR at a James Robinson Ltd. plant (Figure 2.4) (Ni 2006). The total 
process time was reduced drastically from 12 hours to 40 minutes, the reaction yield 
was increased and the reactor footprint was only 5% of the existing one (1200 m3 
compared to 60 m3), even though the daily output remained unchanged (Winder 2003). 
  
 
Figure 2.4 The COBR installed in James Robinson Ltd’s plant is considerably smaller 
than the STR it replaced 
 
 
 
18 
 
Genzyme has recently built the largest-patent protected continuous API 
manufacturing plant in the world, where a COBR is used in one of the synthesis steps to 
produce hundreds of tonnes of a pharmaceutical compound per year. This reactor design 
was chosen primarily because of the reduction in reaction time (30-fold reduction) and 
due to the 99% footprint reduction when the COBR was implemented (2008).  
 
Novartis has recently partnered with the Massachusetts Institute of Technology 
(MIT) to form the Novartis-MIT Centre for Continuous Manufacturing with the 
objective of researching new technologies that can transform current batch-based 
manufacturing processes into fully continuous processes, from start to finish (Trout 
2009). Continuous reactor technologies offer a more simple, predictable and 
controllable solution for pharmaceutical manufacturers together with using less energy 
and solvents, while minimizing the production of waste (Liu et al 1997; Angelucci 
1999; Vervaet and Remon 2005; Crosby 2006). For example, a 10% solvent 
consumption reduction would result in £400k per annum savings for a AstraZeneca’s 
chemical at a production scale case-study (Lawton et al 2009). These and other factors 
will continue to play a significant role in the drive to adopt continuous mixing 
technology. 
 
 
2.2 – Fouling and cross-contamination 
 
2.2.1 – Fouling and Encrustation 
 
If the residues existent inside the reactor are not cleaned systematically and 
periodically fouling might occur and encrustation of these particles on the reactor 
surface can seriously disrupt the normal operation of a manufacturing plant – for 
instance deposition on the bottom of batch reactors can have an important effect on the 
mixing patterns and, therefore, the quality of the product; a simple blockage in pipes 
connecting reactors usually results in the disruption of the production schedule, with a 
possible negative impact in the plant’s cash-flow and reputation. Fouling is defined as 
the accumulation of solid particles at interfaces, such as reactor walls or baffles. Fouling 
is a phenomenon which can take place without a temperature gradient in a great many 
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natural, domestic, and industrial processes, but in the presence of such a gradient, 
fouling or encrustation might be enhanced (Minton 1986). 
  
 
Considering the liquid-solid interface in the reactor, fouling can occur as a result 
of different phenomena. Accordingly, the following classification is based on the key 
physical or chemical process essential to the particular fouling phenomenon. Six 
primary categories have been identified (Minton 1986; Mwaba 2003), of which four 
may have relevance for this project: 
 
1. Precipitation Fouling: crystallization from solution of dissolved substances onto 
the heat transfer surface as the fluid becomes supersaturated with the fouling 
material, and is sometimes called encrustation or scaling (e.g. for acetylsalicylic 
acid or paracetamol, the crystals formed on sub-cooled surfaces might induce the 
formation of fouling); 
 
2. Sedimentation Fouling: the accumulation of finely divided solids suspended in 
the bulk fluid onto the reactor’s surface. In a minority of instances settling by 
gravity prevails, and the process may then be referred to as particulate fouling. 
This type of fouling might occur in the synthesis of methyl diantilis: the solid 
catalyst spheres might become entrapped in the reactor and accumulate on the 
walls and baffles, thereby disrupting normal operation; 
 
3. Chemical Reaction Fouling: the deposit formation on the reactor surface by 
chemical reactions in which the surface material itself is not a reactant. Such 
might be the case with the synthesis of cyalume; 
 
4. Corrosion Fouling: the accumulation of indigenous corrosion products on the 
heat transfer surface, which is caused by the reaction between the species in the 
fluid and the stainless steel, glass or fluoropolymer that form the reactor surface. 
Corrosion products may act as catalysts for other fouling mechanisms, e.g. as the 
reactor surface becomes corroded, there is an increase in nucleation sites, 
promoting undesired sedimentation and crystallization.  
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The net rate of the formation of the deposits is the generally accepted starting 
point for all fouling models. Two competing processes are involved in this – formation 
and removal of the fouling. 
 
The formation of fouling and encrustation involves the following processes 
acting in sequence: 
- processes in the body of the fluid; 
- transport to the reactor surface; 
- attachment/formation of the deposit. 
 
Removal involves one or more of the following: 
- dissolution (material leaves in molecular or ionic form); 
- erosion or reentrainment (material leaves in particulate form); 
- spalling (material leaves as a large mass). 
 
Whereas spalling, or sloughing, takes place at random times and at random 
locations inside the reactor, in a normal process dissolution and erosion are taking place 
continuously across all the deposit’s surface.  
 
The fouling characteristics of a fluid in contact with a reactor surface are a 
function of a variety of parameters: 
 
- properties of the material used in the reactor; 
- geometry of the reactor surface; 
- temperature difference of the boundary region between the fouling liquid and 
the reactor surface; 
- rheology of the system; 
- characteristics of the fouling fluid. 
 
The sequence in which fouling or encrustation occurs for every category of 
fouling mechanism is the following (Minton 1986; Mersmann 2001; Mwaba 2003): 
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1) Initiation of the process (delay, nucleation, induction, incubation, surface 
conditioning); 
2) Transport (mass transfer); 
3) Attachment (surface integration, sticking, adhesion, bonding); 
4) Removal (release, reentrainment, detachment, scouring, erosion, 
spalling, sloughing); 
5) Aging. 
 
1) Initiation - After starting up a process with a clean reactor there is usually a 
short period before any appreciable fouling can be registered. This is called 
the initiation period and it is the time when conditions that make the 
deposition of fouling material onto the surface of the reactor more prone are 
established. In the case of precipitation fouling, it is closely associated with 
the nucleation process of product crystals, which increases with increasing 
degrees of supersaturation. For chemical reaction fouling, the lag period 
usually decreases as the temperature on the internal surface of the reactor is 
increased. If the surface roughness of the reactor is increased, there is a 
tendency for the lag time to be decreased. This can be explained by the fact 
that there is an increase in the availability of sites for nucleation, adsorption, 
and chemical surface-activity, while the small indentations at the surface act 
as a shelter for deposits, which are then protected from the mainstream flow. 
Surface roughness also increases eddy transport to the wall.  
 
2) Transport - This period of the fouling sequence starts when the components 
from the bulk of the fluid travel to the surface of the reactor. There are two 
ways in which this can occur: for sedimentation, precipitation and chemical 
reaction fouling, the fouling material itself is brought from the fluid to the 
surface, but for the corrosion fouling mechanism it is not the fouling material 
that is transported but an ionic species, which contributes to the corrosion 
reaction in the surface of the reactor (e.g. when an strong acid or base is 
being used). This in turn results in the formation of reaction products that 
cause fouling - the transported ionic species acts as a trigger for the deposits’ 
growth. Deposition of fouling substances can either be controlled by 
diffusion or by adhesion. If the rate of diffusion to the walls of the reactor is 
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higher than the rate at which they are adhering to the surface, the deposition 
is adhesion controlled. On the other hand, if the rate of adhesion is much 
higher than the rate of diffusion then the deposition is said to be diffusion 
controlled. During this early stage of deposits formation and encrustation 
there is a tendency for the creation of nuclei on the surface of the reactor or, 
simply by the action of gravity, the particles have a natural tendency to settle 
on a surface where the fluid dynamics of the system are not sufficient to get 
those particle back into suspension. This creates the optimal conditions for 
the formation a crust on the surface of the reactor. To avoid fouling and 
encrustation phenomena the local fluid velocity throughout the reactor has to 
be greater than the minimum velocity at which settling of particles will take 
place; 
 
3) Attachment - Apart from the sedimentation fouling process, the attachment 
of the deposit takes place in the reactor’s wall region, where the solid species 
is formed. The adherence of the different particles to a solid surface depends 
not only on the characteristics of the particles but also on the type and 
smoothness of the surface. Glass, glass-lined material and polished stainless 
steel are generally more favoured than regular steel to be used as reactor 
surfaces. The pipes and ducts should be as smooth as possible and without 
traps that might capture any type of particle. 
 
4) Removal - The speed at which removal phenomenon takes place is directly 
proportional to the mass of deposit and the shear stress on the surface of the 
reactor and the properties of the bulk fluid, and inversely proportional to the 
absorption force of the fouling deposit when interacting with the walls of the 
reactor. The characteristics of the deposit influence the particular removal 
process and it can happen that more than one removal process may occur 
during the period in which fouling is taking place. Dissolving the deposit is a 
way of removing it, and must be accompanied by a change in the 
characteristics of the stream or of the deposit (e.g. changing solvents, the 
temperature or the pH may influence the solubility of the fouling deposit). 
Sloughing and spalling of materials might happen due to changes in the 
characteristics of the deposit or due to changes in stream conditions, but the 
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essential event for sloughing to occur is a change in the character of the 
deposit after its formation that weakens its attachment to the reactor surface. 
Re-entrainment of deposited material by the flowing fluid involves fluid 
mechanical forces and the mutual interaction between the elemental particles 
of the deposit. The most severe problem that can happen in this process is 
when the detachment of crusts takes place: plugging of tubes or pumps may 
occur, leading to operation shutdowns. Not only is this a concern in terms of 
lost operation time, but there is also an increase in energy consumption used 
for the hot water or solvent needed to dissolve the crusts; 
 
5) Aging - The deposit starts to age as soon as it contacts with the reactor 
surface and may comprise changes in the chemical or crystal structure. These 
events may, with time, lead to a strengthening of the deposit in the surface 
but also can trigger the opposite effect – this is visible when a deposit is 
removed suddenly without a change in the normal operating conditions of 
the reactor. 
 
 
Fouling and encrustation or even a simple contamination issue can seriously 
undermine a chemical or pharmaceutical plant’s operation, and on certain occasions 
might lead to a complete halt of the manufacturing process. Genzyme faced this 
scenario recently, when one of its plants had to shut down due to a virus contamination. 
This provoked a shortage of two of Genzyme’s most lucrative drugs, which prompted 
the US Food and Drug Administration (FDA) to consider issuing a $175M fine and to 
allow patients access to competitors drugs, even though these had not been approved for 
human consumption at that time. In that period of time Genzyme’s stock market value 
dropped sharply, with investors considering suing the company (Clarke 2009; Pollack 
2010). It is then of paramount importance to prevent these situations from arising in 
order for a chemical or pharmaceutical plant to operate safely. 
 
 
 One of the major concerns in the chemical industry, especially for those dealing 
with active pharmaceutical ingredients (APIs), is the possibility of having their products 
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contaminated. As delineated by the International Conference on Harmonisation (ICH) 
Guidelines (FDA 2003; FDA 2006), an impurity is a component present in the product 
that is not defined as its chemical entity. In the case of finished products, this definition 
is extended to include any excipients or the product in itself (Basak et al 2007). 
 
 
2.2.2 – Cross-contamination   
 
In the case of chemical and pharmaceutical products, there are two types of 
contaminants: the ones associated with the production process and the ones related to 
the formulation of the finished product or to its aging. Of particular interest to this work 
are the impurities that are formed during the manufacture of the chemical and 
pharmaceutical products. These can be classified as organic contaminants, inorganic 
contaminants and residual solvents (Roy 2002; FDA 2003; FDA 2006; Basak et al 
2007). 
 
Contaminants of organic origin in the product include starting materials, 
intermediates, by-products and degradation products of the chemical reaction, and 
catalysts. It is very rare to obtain a 100% yield in any chemical process and although 
end products are generally isolated with the use of solvents and other purification 
techniques, there is always the possibility that a residual portion of the aforementioned 
types of impurities can still be found in the product – in fact, these are the most 
common sources of impurities and manufacturers have to take extra care to design 
processes that avoid them, or at least diminish their occurrence to acceptable levels. It’s 
interesting to note that in the case of some pharmaceutical products, enantiomeric forms 
of the product other than the one considered to be the most effective can be classed as 
an organic impurity, and as such have to be removed from the final product. 
 
Contaminants classed as inorganic include reagents, ligands and catalysts, heavy 
metals and other substances (such as activated carbon or filter aids). Contamination of 
the product by heavy metals can occur when non-demineralized water is used in 
stainless steel where an acidification or acid hydrolysis is taking place. The use of USP 
water and glass-lined reactor is essential to prevent contaminations of inorganic origin. 
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The very nature of solvents and its widespread use in chemical processes means 
that it’s very difficult to completely remove residues of this kind. However, due to their 
toxicity factor, the presence of solvent residues in the finished products must be avoided 
(class 1 – known or suspected human carcinogens, environmental hazards) or reduced to 
acceptable levels (classes 2 and 3 – non geno-toxic animal carginogens and solvents 
with low toxic potential hazard, respectively), as described in the ICH guideline Q3 
(Roy 2002; Basak et al 2007). 
 
The contaminations may also result from a series of diverse factors - e.g. 
introduction of the wrong ingredients; introduction of out-of-date, damaged or 
contaminated ingredients; microbial growth inside the piping or vessel and, of particular 
interest to this project, contamination from a previous batch if the vessel or piping was 
badly cleaned. It is of utmost importance to control and reduce the occurrence of these 
events, both through the intelligent design of the chemical reactor – avoiding the use of 
pipes of different diameter and “dead-volume” areas where contaminants can settle – 
and through the use of a cleaning procedure that guarantees a degree of cleaning of the 
reactor that is up to the stringent standards set by regulatory organizations (Gambrill 
1995; Argentine et al 2007; Basak et al 2007). 
 
 
2.3 – Fouling Prevention and Cleaning 
 
 Until fairly recently the typical industrial approach to cleaning was empirical 
and not based on concrete and studied measures to tackle this issue (Perka et al 1993). 
However, with the increased stringency concerning the purity of produced APIs and 
other fine chemicals enforced by regulatory agencies around the world, there is a current 
drive towards better cleaning standards and practices. Another factor influencing 
chemical companies to take actions to reduce waste and energy use is public opinion. In 
an age when global warming and climate change are receiving so much media attention, 
companies are putting an extra effort to be perceived as environmentally-friendly, 
therefore raising their profile; even in a sector traditionally regarded as being very 
polluting such as the pharmaceutical sector, there are good examples of this trend, with 
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companies such as Bayer and Bristol-Myers Squibb leading the way in the efforts to 
reduce toxic emissions and generated waste (Marwaha 2007). 
 
Prevention of fouling and waste generation can be done by monitoring the 
operation conditions and synthetic route more closely, in order to maximize the 
efficiency of the process. For example, in cooling crystallization fouling and 
encrustation problems can be greatly reduced by minimizing the temperature difference 
between the jackets and the solution in the reactor. In theory, encrustation can be 
eliminated if this temperature differential is inferior to the width of the metastable zone, 
because larger temperature differences can increase the possibility of spontaneous 
crystal formation to occur. Using a reactor in which the surface-to-volume ratio is small 
increases the heat transfer efficiency and reduces this risk (Mullin 2007; Wieckhusen 
2008; Tung, Paul et al 2009). 
 
Nonetheless, in large-scale conventional reactors it’s almost impossible to 
completely eliminate these factors and therefore process down-time is required, 
lengthening turnaround times and reducing yields, thereby increasing operational costs 
(Chew et al 2006). In order to proceed to the cleaning stage between different batches, 
conventional mixers normally have to be disassembled and often require off-line time-
consuming cleaning of parts to prevent contamination. That might also be another 
source of contamination, since typically these cleaning procedures are done while the 
vessel is in contact with the outside atmosphere (Gambrill 1995). Although the cleaning 
of vessels has always been a potential source of contamination and waste, it is necessary 
to put in place a more cost effective solution to reduce waste generation and cleaning 
times. While the cleaning of STRs is seen as time-consuming, the cleaning of plug-flow 
reactors is perceived to be a costly procedure (Coker 2001). 
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2.3.1 – The Cleaning Continuum 
 
Given the variety of facilities, manufacturing processes and final products in the 
chemical and pharmaceutical industry and in the absence of a universal approach to 
cleaning, a cleaning continuum has been established. This concept can be defined as an 
“organizational model that helps to draft the operational details of a specific cleaning 
validation programme” (Potdar 2007). By coupling several opposed extremes that 
represent current industry cleaning practices, the cleaning continuum serves as a guide 
in order to establish the most appropriate cleaning validation protocol (Table 2.1). 
 
 
Table 2.1 The cleaning continuum 
(Note: The extremes which are more attuned with this project are in bold) 
 
Manual ................................................... Automated Cleaning 
Clean-out-of-Place (COP) ................................................... Clean-in-Place (CIP) 
Dedicated Equipment ................................................... Non-Dedicated 
Equipment 
Product Contact 
Surfaces 
................................................... Non-Product Contact 
Surfaces 
Minor Equipment ................................................... Major Equipment 
Low Risk Drugs ................................................... High Risk Drugs 
Highly Characterized ................................................... Poorly Characterized 
Sterile ................................................... Non-Sterile 
Soluble  ................................................... Insoluble 
Campaigned Production  ................................................... Non-Campaigned 
Production 
 
  
 An advantage of using automated cleaning is that it is easier to reproduce and 
will yield more reproducible results. This type of operation suits continuous reactors. 
The validation of the automated procedure is done using sampling and analytical 
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techniques that have been extensively used in the industry with proven results (Madsen 
1998). 
 
 The cleaning of continuous reactors can be done using a single-path cleaning-in-
place (CIP) procedure that does not require cleaning to be done in contact with the 
outside environment, which reduces process downtime, waste, risk of cross-
contamination and brings operational costs down. Moreover, the cleaning conditions 
(e.g. temperature, pH, high detergent concentration) used while performing CIP can be 
more extreme due to the fact that there is no direct operator contact with the cleaning 
solution (Perka et al 1993; Gambrill 1995; Bismuth and Neumann 2000; Chew et al 
2006).  
  
Chemical reactors are often not used as dedicated equipment, in the sense that 
they may be used to perform different tasks, according to the plant’s requirements. 
Cross-contamination is a possible occurrence if the cleaning procedure is not well 
designed or performed and so particular attention is put in the detection of residues, in 
both the cleaning and production phases.  
 
The cleaning procedure can be designed towards detecting residues and 
contaminant species inside the reactor when using closed continuous reactors, in which 
reactants, products and possible by-products of the reactions to be performed will be in 
direct contact with its walls. When considering a manufacturing process, the chemical 
reactor plays a central role and as such it is considered as a “major equipment”. 
Therefore, materials of construction have to be carefully selected to ensure excellent 
chemical and temperature resistance. Due to their non-reactive characteristics and 
smooth surfaces (low friction coefficients make the deposition of residues more difficult 
to occur) materials such as glass, stainless steel or fluoropolymers are usually chosen 
when considering the design of a reactor to be used in the manufacture of fine chemicals 
and APIs (Madsen 1998). 
 
In order to pass regulatory norms and get their products on the market, 
manufacturing companies have to be able to characterise extensively the chemical 
entities that are included in the process. These pose various degrees of health risks and 
knowing the safe limits of exposure constitutes an added layer of protection for both the 
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operators of the reactor and final users of the products being made. This is why it is 
important to determine appropriate cleaning acceptance criteria, based both on the 
allergenicity/toxicity/mutagenicity/potency of the chemical entities and on the 
characteristics of the reactors being used in the specific manufacturing processes 
(Madsen 1998; LeBlanc 2000).    
 
Sterile facilities have to ensure that while in operation no microbial life or 
endotoxin will contaminate the system. Generally, the reaction conditions present in a 
typical fine chemical or API production campaign are considerably harsh either because 
of the high temperatures or strong acids or bases are used. As such, the possibility of 
contamination of the reactor by the aforementioned agents is not a very likely event to 
happen. On the other hand, the residues that might indeed remain in the reactor before 
the cleaning stages start are normally expected to be soluble and will be easier to rinse 
out, making cleaning a more simple process. 
 
The planned experimental work to be undertaken in the COBR for this project 
includes week-long production campaigns of three different chemical entities. Apart 
from testing the capability of the COBR as a suitable alternative chemical reactor from 
the production point of view, the cleaning procedure to be put in place must be 
adequate, verifiable and reproducible (Scarso 1996; Rios 2007). 
 
 
2.4 – From quality-by-analysis to quality-by-design 
 
The chemical and pharmaceutical industries are traditionally batch-oriented. 
Processes devised and registered with regulatory agencies decades ago are still in use 
and are not easy to be changed. Due to factors such as the existence of patents or due 
the simple fact that processes in place “work” and generate a constant stream of profit 
there is no urgency in making these same manufacturing processes more efficient and 
making the shift from batch to continuous unless this change is driven by the ever more 
stringent quality criteria being put in place or by the fierce competition existent in the 
chemical and pharmaceutical industries (Malhotra 2009).  
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Quality concerns and regulatory bodies dictate that a plant that operates in a 
batch fashion must test each product batch and check if it conforms to all the quality 
parameters.  In a world where quality parameters are increasingly more stringent this 
“quality-by-analysis” approach might serve as a safety blanket, but it also means that 
expensive testing equipment must be used (Malhotra 2008). The testing procedures 
frequently take a long time to be performed and all the while the whole batch cannot be 
moved out of the plant, adding further financial strain because adequately dimensioned 
facilities have to be built in order to store the plant’s production. Furthermore, if a batch 
that has been stored - while samples are being tested - does not meet the required quality 
criteria, all of it has to be discarded or reprocessed. The treatment of waste APIs that are 
not good enough to be marketed is in itself an expensive process and regarded as anti-
ecological.  
 
Together with compliance and supply chain issues, a different approach to 
product quality has also been driven by the expiration of patents and the dwindling 
number of new molecular entities that are approved to market each year by regulatory 
agencies. Chemical, and in particular, pharmaceutical companies are being forced to 
find ways in which to optimize manufacturing processes in order to remain competitive 
(Malhotra 2008; Cook, Venkateshwaran et al 2009). The “quality-by-design” (QbD) 
approach, whereby entire processes are designed from the beginning with a profound 
knowledge of the chemistry and the variables involved, is associated with continuous 
manufacturing.  
  
 Designing product quality into a continuous process instead of addressing 
quality at the end of the production stage ensures that the chemical or API being 
manufactured is of the highest and most consistent quality. Process Analytical 
Technologies (PAT) is an essential feature of QbD and includes all analysis (chemical, 
physical, microbiological, etc) done in-process, in a timely manner.  According to the 
FDA, PAT is a “system for designing, analyzing, and controlling manufacturing through 
timely measurements (i.e., during processing) of critical quality and performance attributes 
of raw and in-process materials and processes, with the goal of ensuring final product 
quality. The goal of PAT is to enhance understanding and control the manufacturing 
process, which is consistent with our current drug quality system: quality cannot be tested 
into products; it should be built-in or should be by design.” (CDER 2004).  
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In addition to the above-cited guideline, other published material shows how 
important the drive for the adoption of continuous manufacturing has been in recent 
times. This is the subject of the following section. 
 
 
2.5 - Regulatory Bodies and Good Manufacturing Practices 
 
In order to sell their products, pharmaceutical companies must be aware of 
current regulations of the markets where they want to operate. For example, if the 
product is to be marketed in the USA, it has to be compliant with the requirements set 
by the FDA; similarly, if it wishes for its product to be marketed in Japan, it has to 
comply with the Japanese Ministry of Health, Labour and Welfare (MHLW) 
regulations. Global manufacturers have also to operate in compliance to rules and 
guidance set out by the International Society of Pharmaceutical Engineers (ISPE) and 
the World Health Organization (WHO). 
 
Because of the increasing globalization effects, there has been an effort in recent 
years towards harmonization of these rules in international markets. Following the birth 
of the International Conference on Harmonization (ICH) in April 1990 there has been a 
continuous effort to bring “together the regulatory authorities of Europe, Japan and the 
United States and experts from the pharmaceutical industry in the three regions to 
discuss scientific and technical aspects of product registration”1. For example, the 
“Rules Governing Medicinal Products in the European Union”, Volume 4, published by 
the European Commission concerning Good Manufacturing Practice (GMP) is in 
accordance with “FDA Good Manufacturing Practices for Finished Pharmaceuticals”; 
additionally, these two sets of rules are consistent with ISPE good automated 
manufacturing practice. Japan’s pharmaceutical affairs law also had to undergo major 
changes in order to make it comparable to the Western world rules and regulations on 
GMP (Bonanomi 2006). 
 
                                                 
1 In www.ich.org 
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In the European Union and the European Economic Area2 a framework of laws 
and regulations is in place in order to ensure the good functioning of the chemical 
products market. Since 1965, when the Council Directive 65/65/EEC on “the 
approximation of provisions laid down by law, regulation or administrative action 
relating to medicinal products” was put in place, there has been a continuous effort to 
regulate the market, in the form of several other directives and amendments to 
directives.  
 
Nowadays, as a result of Title IV of Directive 2001/83/EC (last amended in 
2004), Governments of Member States have to ensure that pharmaceutical 
manufacturers are authorized to operate, in accordance, among other requirements, to 
GMP. The guidelines and principles of GMP for medicinal products for human use are 
described in Directive 2003/94/EC and the European Community Guide to GMP 
includes elements from ISO 9001:2000 with additional requirements specific to 
medicines; in the UK, these regulations and other are described in the Rules and 
Guidance for Pharmaceutical Manufacturers and Distributors, compiled by the 
Inspection and Standards Division of the Medicines and Healthcare products Regulatory 
Agency (MHRA), and is also commonly known as the “Orange Book” (MHRA 2007).  
 
In order to be authorized to produce and market chemicals, a company must 
comply with the country’s regulatory body’s requirements in order to reduce the risk to 
the client due to inadequate safety, quality or lack of efficacy. In particular to the case of 
medicinal products and APIs, the manufacturer has to have in place “a comprehensively 
designed and correctly implemented system of Quality Assurance incorporating Good 
Manufacturing Practice and thus Quality Control”3.  
 
With particular relevance to this work there is the definition and scope of GMP, 
the requirements on premises and equipment4, documentation5, production (with special 
attention to the “Prevention of Cross-contamination in Production” sub-section)6, the 
regulations on buildings and facilities (namely those pertaining to the design and 
                                                 
2 This includes the EU countries plus Iceland, Liechtenstein and Norway  
3 in Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2007, p. 43, London, 
Pharmaceutical Press. 
4 Described in Chapter II, Part I, Section 3 of the “Orange Book” 
5 Described in Chapter II, Part I, Section 4 of the “Orange Book” 
6 Described in Chapter II, Part I, Section 5 of the “Orange Book” 
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construction sub-section)7, process equipment8, guidelines for documentation and 
records9 and for the production and process controls (with particular attention to the 
contamination control subsection)10. 
 
As defined in the “Orange Book”, GMP is “that part of Quality Assurance which 
ensures that products are consistently produced and controlled to the quality standards 
appropriate to their intended use and as required by the Marketing Authorization or 
product specification. 
 
GMP is concerned with both production and quality control. The basic 
requirements of GMP are that: 
 
(i) all manufacturing processes are clearly defined, systematically 
reviewed in light of experience and shown to be capable of 
consistently manufacturing medicinal products of the required quality 
and complying with their specifications; 
(ii) critical steps of manufacturing processes and significant changes to 
the process are validated; 
(iii) all necessary facilities for GMP are provided including: 
a. appropriately qualified and trained personnel; 
b. adequate premises and space; 
c. suitable equipment and services; 
d. correct materials, containers and labels; 
e. approved procedures and instructions; 
f. suitable storage and transport; 
(iv) instructions and procedures are written in an instructional form in 
clear and unambiguous language, specifically applicable to the 
facilities provided; 
(v) operators are trained to carry out procedures correctly; 
(vi) records are made, manually and/or by recording instruments, during 
manufacture which demonstrate that all the steps required by the 
                                                 
7 Described in Chapter II, Part II, Section 4 of the “Orange Book” 
8 Described in Chapter II, Part II, Section 5 of the “Orange Book” 
9 Described in Chapter II, Part I, Section 6 of the “Orange Book” 
10 Described in Chapter II, Part I, Section 8 of the “Orange Book” 
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defined procedures and instructions were in fact taken and that the 
quantity and quality of the product was as expected. Any significant 
deviations are fully recorded and investigated; 
(vii) records of manufacture including distribution which enable the 
complete history of a batch to be traced, are retained in a 
comprehensible and accessible form.”  
 
 
The relevant regulations for this work and the adequate measures taken are 
described in Table A.1 in the Appendix A. 
 
In addition to this, regulatory bodies have recently published guidelines with the 
purpose of making manufacturers fully understand and optimize the way their 
pharmaceutical products are developed, evaluated and manufactured, such as the 
Critical Path Initiative (CPI) issued by the FDA or the Q8 guideline published by the 
ICH guideline which focuses on QbD. These regulatory efforts present the perfect 
opportunity for continuous process technology to be embraced and to be successfully 
implemented (ICH 2006; FDA 2009). 
 
 
2.6 - Acceptable Limits of Cross-Contamination  
 
In order to have a sound cleaning procedure, there is the need to set limits with 
regard to contamination, most critically in APIs and their finished products. While the 
FDA merely affirms that residue limits must be logical, practical, achievable, and 
verifiable in its publication “Guide to Inspections of Validation of Cleaning Processes” 
(1993), the same regulatory agency, in light of the ICH, has published a set of limits for 
impurities in drug substances and drug products (FDA 2003; FDA 2006) (Tables 2.3 
and 2.4).  
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Table 2.2 Applicable thresholds for impurities in new drug substances. Notes: 1- Higher 
reporting thresholds should be scientifically justified; 2 - Lower thresholds can be 
appropriate if the impurity is unusually toxic. Source: FDA, USA. 
 
Maximum 
Daily Dose (g) 
Reporting 
Threshold (1,2) 
Identification 
Threshold (2) 
Qualification Threshold 
(2) 
 
≤2 
 
0.05% 
 
0.10% or 1.0 mg per 
day intake 
(whichever is lower) 
 
0.15% or 1.0 mg per day 
intake (whichever is 
lower) 
 
> 2 
 
0.03% 
 
0.05% 
 
0.05% 
 
 
Table 2.3 Applicable thresholds for degradation products in new drug products. Notes: 
1- Higher reporting thresholds should be scientifically justified; 2 - Lower thresholds 
can be appropriate if the impurity is unusually toxic; 3 – whichever is lower; TDI – 
Total Daily Intake. Source: FDA, USA. 
 
Maximum 
Daily Dose 
Reporting 
Threshold (1,2) 
Identification 
Threshold (2) 
Qualification Threshold (2) 
 
≤ 1  g 
 
0.1% 
  
> 1 g 0.05%   
< 1 mg  1.0% or 5 µg TDI (3)   
1 mg - 10 mg  0.5% or 20 µg TDI (3)  
>10 mg - 2 g  0.2% or 2 mg TDI (3)  
>  2 g  0.10%   
< 10 mg   1.0% or 50 µg TDI (3) 
10 mg - 100 mg   0.5% or 200 µg TDI (3) 
>100 mg - 2 g   0.2% or 3 mg TDI (3) 
> 2 g   0.15% 
 
 
The regulatory bodies do not set limits of acceptable contamination for specific 
manufacturing processes. That is the responsibility of the manufacturer, and the limit set 
must be sufficient to guarantee that the bulk API or finished product conform to the 
quality requirements. It is, therefore, of utmost importance to clearly define residue 
limits both in APIs, finished products and also in the manufacturing equipment used due 
to the possible effects those can have in public health (LeBlanc 2000; Basak et al 2007). 
36 
 
A particularly relevant study about acceptable contamination levels was carried out by 
LeBlanc (2000) and limits are defined in the following way:  
 
Considering BL1 as the limit of the target residue (in this case, the target residue 
is the bulk active APIA) in any finished drug product in which the residue may 
ultimately be found, it is calculated as: 
 
SF1000000
Prod of dosedaily  minimum
API of dosedaily  minimum  BL
B
A
1 ××





=  (2.3) 
 
 
APIA – Bulk active A. 
 
ProdB – Finished product B 
 
SF – Safety Factor (= 0.001) 
 
 
Taking BL2 as the limit of the residue in the API used in the manufacture of the 
finished drug: 
 
 






×=
B B
12 Prodin  API %
100 BL BL   (2.4) 
 
 
 
 Cross-contamination levels can then be set and safety limits of operation can be 
established when the production of different chemicals are involved, as in this project, 
ensuring that the manufactured chemical and pharmaceutical entities respect the quality 
guidelines currently in place. 
 
 
 2.7 – Summary 
 
 The relevant background information covering OBR and COBR, fouling and 
cross-contamination, cleaning strategies, regulatory guidelines and acceptable limits of 
cross-contamination is reviewed in this chapter. While it is evident that extensive work 
has been carried out in order to understand the characteristics and possible applications 
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for the OBR, the work herein described is the first to investigate the robustness and 
adaptability of the COBR to different synthesis of chemical and pharmaceutical entities 
in tandem. It is also the first to establish a reliable, fast and cost-efficient cleaning 
procedure that satisfies the current regulatory guidelines in a GLP/GMP environment.    
38 
 
Chapter 3  
 
EXPERIMENTAL APPARATUS 
 
 
 
An experiment is a question which science poses to Nature,  
and a measurement is the recording of Nature's answer.  
 
Max Planck, physicist 
 
 
This chapter is dedicated to the description of the equipment used in the 
experiments carried out in the OBR and COBR, as well as in the analytical assessment. 
There are three main sections in this chapter: the first addresses the OBR experimental 
setup, the second focuses on the planning, design and setup of the continuous work and 
the last section describes the analytical methods used to assess the quality of the work 
executed.  
 
 
3.1 – The Setup of OBR 
 
 A description of the OBR setup used for batch studies of the various chemistries 
is presented in this section.  
 
The OBR was 25 mm in diameter and had a total working volume of 60 mL. 
Figure 3.1 shows the OBR with the baffle set, when dismounted from the supporting 
frame. Figure 3.2 represents the scheme of the used OBR.  
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Figure 3.2 Scheme of the OBR 
A – Sew Eurodrive motor; B – Temperature reading unit; C – PTFE lid; D – Supporting 
frame; E – Baffle set; F – Thermocouple; G – Glass-jacketed OBR; H – Discharge valve 
 
Figure 3.1 Photo of the batch OBR 
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The reactor was made of jacketed glass in order to perform temperature-
controlled experiments and has a burette-style valve at the bottom for sampling. The 
used baffle set was made of stainless steel plates; the baffles had a thickness of 3 mm 
and the internal diameter was 13.5 mm. The distance between the baffles is 33.5 mm. 
The oscillation was provided by a SEW Eurodrive motor and was controlled by a SEW 
Eurodrive frequency inverter. The hot water that circulated inside the OBR jacket 
during the experiments was provided by a Grant W28 hot water bath and a K-type 
thermocouple (limit of error ±0.55 oC) fitted through the OBR top was used for 
temperature control. 
 
 
3.2 – The Setup of COBR 
 
A COBR was purposefully designed and built to specifications in order to carry 
out the selected synthesis of the fine chemical and active pharmaceutical ingredients. 
The reactor has an internal diameter of 15 mm and a total working volume of circa two 
litres. Figure 3.3 is a photo of the reactor, which is supported by an aluminium frame. 
The COBR was made of jacketed glass with PFA (perfluoroalkoxy) baffles and 
composed of 15 glass sections, each 700 mm long. Each baffle was 22.7 mm apart from 
the others and 3mm thick with an internal diameter of 7.5 mm. PFA was the baffle 
material of choice because it belongs to a class of compounds known to have the lowest 
surface energy of all solid materials and a fully fluorinated, micro-void free surface, 
which makes this a non-stick material (McKeen 2006). Those characteristics coupled 
with the fact that PFA is virtually chemically inert and the possibility of using it at 
temperatures up to 260 oC (Fleming et al 2001) make it ideal to be used in the type of 
chemical reactions to be undertaken in the COBR, where strong acids and high 
temperature are going to be used. The use of any other common and cheaper materials 
for the construction of the reactor would carry the risk of chemical or heat degradation. 
Product deposition and encrustation is also a phenomenon that is reduced by using PFA.  
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Figure 3.3 Photo of the COBR 
 
 
The following scheme (Figure 3.4) details the COBR setup, with the relative 
location of the valves, ports, thermocouples and pressure gauges. The assembly of the 
COBR was carried out by NiTech Solutions Ltd. 
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Oscillation was provided by the Copley Controls Corp. XTA38 servotube 
actuator connected to the PTFE bellows, which provide the linkage to the COBR 
(Figure 3.5). The actuator is controlled by a purpose built control unit, which allows a 
fine control over frequency and amplitude. 
 
  
  
Figure 3.4  Layout of the COBR:  
B – Bellows;  
F1 and F2 – Feed valves;  
P1 to P3 – Pressure gauges; 
PV – Product 3-way valve;  
S1 to S4 – Sampling valves;  
T1 to T4 – Thermocouples;  
V1 to V4 – Purge valves (V3 and V4  
can also be used as sampling valves). 
Figure 3.5 The Copley Controls XTA38 actuator.  
Source: Copley Controls – Division Analogic Corporation 
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 The COBR was equipped with two entry ports and two discharging ports. The 
latter ports were controlled via a 3-way valve. The sampling of the reaction mixture 
inside the reactor was done via four sample ports located along the reactor. Located at 
each top bend there are the purge valves which can also function as sample ports. In 
order to control the operational conditions four K-class thermocouples (limit of error 
±0.55 oC) and three pressure gauges (0-4 bar) were fitted at different locations along the 
COBR shown as T1-T4 and P1-P3 in Figure 3.4. All the 36.5 mm long sleeves that 
connect the glass tubes, valves, taps and pressure gauges were made of stainless steel 
316 with BSP threads.  
 
The product hoses were made of temperature and chemical resistant non-
corrugated FEP (Flourinated Ethylene Propylene) and have an internal diameter of 14.7 
mm. The entry ports are connected to chemically resistant Chem-Durance® peristaltic 
pump ready tubes, with an internal 
diameter of 7.9 mm. 
 
Two Watson-Marlow 520S pumps 
(Figure 3.6) were employed to pump the 
starting materials and solvents into the 
COBR, ensuring that the range of 
operational flowrates used are covered. 
One of the COBR’s entry ports was 
connected to a purpose-built feeder DN80 
glass-jacketed OBR, which is supported 
by an aluminium frame located inside the 
fume hood.  
 
The OBR feeder had a total volume capacity of 1000 ml and can be sealed with 
a PTFE lid, as a first barrier for developing fumes. It was equipped with 3 entry ports 
(internal diameters of 22.2 mm, 17.2 mm and 12.7 mm, respectively) and a PTFE tap-
controlled outlet port. The baffle set was made of PTFE connected by stainless steel 
rods, with an interval of 113 mm. The baffles had an internal diameter of 34.7 mm and 
are 3.4 mm thick. These materials were chosen due to their high chemical and heat 
resistance, and were found adequate for the chemistry being studied. The motor that 
Figure 3.6 The Watson-Marlow 520S 
peristaltic pump, used to pump 
starting materials to the COBR.  
Source: Wtson-Marlow Bredel 
Pumps – Spirax-Sarco Engineering 
Group 
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drives the baffle set was a Parvalux RS718-010 - a powerful and small-footprint unit - 
and was controlled by a Eurotherm 650 frequency inverter. Figure 3.7 shows the 
assembled OBR in the supporting frame. This setup was placed inside a fully ventilated 
fume hood for safe operation. 
 
 The hot water was provided to the 
COBR and the OBR feeder via two water 
baths: Grant W28 and Grant Y28, both with 
28 litres of capacity and a maximum working 
temperature of 99 oC (Figure 3.8). 
 
 
 
 
 
Figure 3.7 The batch OBR feeder 
Figure 3.8 Grant W28 water bath 
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3.3 – Materials 
  
This section describes the materials used for each of the experiments carried out 
in this project. 
 
 3.3.1 - Bis(2,4,6-trichlorophenyl) oxalate 
 
 All the reactants used for this experiment were supplied by Sigma-Aldrich (St. 
Louis, USA). The 2,4,6-trichlorophenol 98% (code T55301-50G) used was is powder 
form and had a light brown appearance. Triethylamine >99% (code T0886-100ML) was 
a colourless liquid with an amine-like odour. Oxalyl chloride >99% (code 221015-25G) 
was a pungent, clear liquid. The solvent used, anhydrous toluene 99.8% (code 244511-
1L), was a colourless liquid. Anhydrous hexane 95% (code 296090-1L), used for the 
vacuum filtration, was a clear liquid.   
 
 
 3.3.2 - Methyl diantilis 
 
 Methanol and amberlyst-15 were sourced from Sigma-Aldrich (St. Louis, USA). 
3-ethoxy-4-hydroxybenzyl alcohol was acquired from Fluorochem (Glossop, UK).  
Acting both as reaction medium and reactant, anhydrous methanol 99.8% (code 
322415-1L) was a colourless liquid. The catalyst used, amberlyst-15 (code 216380-
25G), was in the form of light yellow spherical pellets that had to be treated with 
methanol before being used in the experiment. 3-ethoxy-4-hydroxybenzyl alcohol (code 
018670) had a white powder appearance.   
 
 
 3.3.3 – Vanisal sodium 
 
 Vanillin and sodium hydrogen sulphite was purchased from Sigma-Aldrich (St. 
Louis, USA). The purified water used was sourced from Heriot-Watt University 
(Edinburgh, UK). Vanillin 99% (code V1104-100G) had a very light yellow powder 
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appearance  and sodium hydrogen sulphite 40% solution (code 13438-1L-R) was a clear 
liquid. 
 
 
 3.3.4 – Acetylsalicylic acid 
 
 The salicylic acid, acetic anhydride and sulphuric acid used for this experiment 
were acquired from Sigma-Aldrich (St. Louis, USA). The purified water, used to 
decompose excess acetic anhydride and in the vacuum filtration, was sourced from 
Heriot-Watt University (Edinburgh, UK). Salicylic acid >99% (code 247588-500G) had 
a white crystalline appearance. The acetic anhydride >99% (code 320102-1L) used was 
a pungent, colourless liquid. Sulphuric acid 95-98% (code 320501-1L) was a clear, 
thick liquid. 
 
 
3.3.5 – Paracetamol 
 
 The p-aminophenol and acetic anhydride used were acquired from Sigma-
Aldrich (St, Louis, USA). The purified water, used as a solvent and also in the vacuum 
filtration, was sourced from Heriot-Watt University (Edinburgh, UK). The p-
aminophenol 98% (code A71328-1KG) used had a light brown powder appearance.  
The acetic anhydride used had the same origin as the one utilized for the acetylsalicylic 
acid experiments. 
 
 
 
 
3.4 – Analytical Equipment 
 
 The following section describes the analytical instrumentation that was used to 
analyze the samples taken from the experiments. The equipment covers a wide range of 
analytical techniques: Infrared Spectroscopy, Nuclear Magnetic Resonance 
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Spectroscopy, High Performance Liquid Chromatograpy, Scanning Electron 
Microscopy, X-Ray Diffractometry and Particle Size Distribution. 
 
 
3.4.1 – Infrared Spectroscopy 
 
 Infrared spectroscopy (IR) was used to analyze the Bis(2,4,6-trichlorophenyl) 
oxalate and methyl diantilis produced. The equipment used at Heriot-Watt University 
was a Perkin Elmer Spectrum FT-IR System (Figure 3.9). For the cyalume analysis the 
KBr pellet technique was used, whereas to analyse the fragrance tetrafluorocarbon-
washed glass disks were used. 
 
 
 
 
 
 
 
 
 
   
 
Figure 2.9 The Perkin Elmer Spectrum FT-IR system used (Organic Chemistry 
laboratory, Heriot-Watt University) 
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3.4.2 – Nuclear Magnetic Resonance Spectroscopy 
 
 
The produced vanisal sodium was analyzed using Nuclear Magnetic Resonance 
(NMR) spectroscopy. The equipment used at Heriot-Watt University was a Bruker 
DPX400 NMR spectrometer (13C at 100 MHz) equipped with pulsed field gradients, as 
illustrated in Figure 3.10. 
 
 
 
3.4.3 – High Performance Liquid Chromatography 
  
 The High Performance Liquid Chromatography (HPLC) equipment used at 
NiTech Solutions Ltd was a Varian Prostar 230 (Figure 3.11) and the method used for 
analysing both acetylsalicylic acid, paracetamol and vanisal sodium was an adaptation 
of the method developed by Franeta et al (2002): the chromatography column was a 
reverse-phase YMC ODS-AQ (250 x 4.6 mm; 5 μm packing), the UV detector was set 
at 254 nm and the mobile phase was composed by acetonitrile (A) and water with 
phosphoric acid at pH 2.6 (B). In each run the chromatography program was started 
with 10% v/v of A and 90% v/v of B, with a flow rate of 1 mL min-1. The mobile phase 
composition was then gradually transformed to 100% of A over a period of 20 minutes 
and the program was stopped at 25 minutes. 
Figure 3.10 Bruker DPX400 NMR spectrometer 
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3.4.4 – Scanning Electron Microscopy 
 
 Scanning Electron Microscopy (SEM) was used to observe in detail samples of 
the acetylsalicylic acid and paracetamol crystals produced. These were imaged using a 
Hitachi S-2700 Microscope (Figure 3.12), available at the Chemistry Department in 
Heriot-Watt University. The crystals were gold coated and then observed at a 
magnification of 30× and 200×, using 10 kV accelerating voltage. 
 
 
 
 
Figure 3.11 Varian Prostar 230 used for HPLC analysis   
Figure 3.12 Hitachi S-2700 Microscope used for SEM analysis 
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3.4.5 – X-Ray Diffractometry  
 
X-Ray Diffractometry (XRD) was carried out to determine the diffraction 
patterns of the acetylsalicylic acid and paracetamol produced. A Bruker D8 Discover 
transmission X-Ray diffractometer with a Cu-Kα target, pictured in Figure 3.13, was 
used. The tube voltage and current was 40 kV and 40 mA, respectively and the θ angle 
increments of two degrees. The gathered data was obtained using the wide angle x-ray 
scattering (WAXS) technique and the EVA data handling package was used to process 
the results. It is available in the Chemistry Department at Heriot-Watt University.  
 
 
 
3.4.6 – Particle Size Distribution 
 
A Malvern Mastersizer S equipped with a liquid sample holder, available at the 
Institute of Petroleum Engineering in Heriot-Watt University (Figure 3.14), was used 
for particle size distribution studies of the paracetamol crystals produced. After testing 
Figure 3.13 Bruker D8 Discover transmission X-ray diffractometer used for XRD analysis   
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several liquid media, Multipar H oil was found to be the best in order to suspend the 
studied particles.  
 
 
Figure 3.14 Malvern Mastersizer S used for particle size distribution studies 
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Chapter 4  
CHEMISTRY SCREENING 
 
 
Just as houses are made of stones, so is science made of facts;                                      
but a pile of stones is not a house and a collection of facts is not necessarily science. 
Henri Pointcaré, mathematician, philosopher of science 
 
 
 The selection process for the chemical entities to be studied in a batch OBR and, 
subsequently, in continuous fashion using a COBR began by screening different 
chemistries. A series of criteria were established in order to narrow down the potential 
candidates to a maximum of three. These were: 
 
1. Type of chemistry 
 
Considering that the OBR/COBR mixing technology is suitable for a wide range 
of chemistry, pharmaceutical and food processes (see Chapter 2), this work is 
focused on the fine chemicals and pharmaceuticals. 
  
2. Industrial relevance 
 
This PhD project is sponsored by EPSRC and NiTech Solutions Ltd. via an 
EPSRC industrial CASE studentship. The chemistries that are relevant to 
NiTech Solutions Ltd. are industrially driven, with a particular emphasis on the 
pharmaceutical market. 
 
3. Cost 
 
The cost of carrying out the experiments was one of the major factors that shape 
the scope of the project. With a final objective of carrying out a week-long 
production run for each of the three selected chemical reactions, the overall costs 
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for the equipment (e.g. COBR), consumables (e.g. solvents and reactants) and 
analytical tests must be within the limited budget. 
 
4. Reaction time 
 
Bearing in mind the budget of the project, the reaction time should ideally be 
less than one hour in literature, ensuring that the reactor will not be too long and 
thus expensive; 
 
 
4.1 – Chemistries excluded 
 
 
With the objective of proving that the OBR/COBR design can be a viable 
alternative to the stirred tank reactor in the manufacture of fine chemicals and 
pharmaceuticals both in terms of efficiency of the process and quality of the products 
obtained, several different chemistries were initially considered for this project. Four of 
them were excluded from experimental studies due to factors such as cost of starting 
materials, cost of having to use more equipment associated with the synthetic or 
isolation steps or simply because the experimental workup required time-consuming 
steps (eg. sample treatment for analysis) that prevented a single operator to carry out the 
experiments in a focused and safe manner.  These chemistries, described in the 
following sections, were warfarin sodium, nitisinone, tesmilifene and acamprosate 
calcium.  
 
 
4.1.1 – Warfarin sodium 
 
Warfarin sodium is a well-know and established anticoagulant drug and 
powerful rodenticide (Ashkar et al 2004). The name is derived from the initials of the 
Wisconsin Alumni Research Foundation, the organism that provided funding for initial 
research into this chemical entity to Karl Link, a professor at the University of 
Wisconsin (Link 1959).  
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Link’s work on warfarin was first motivated by a series of unexplained cattle 
deaths in the 1920’s. These deaths were later associated with spoiled hay made from 
sweet clover that caused cattle death by severe haemorrhaging. Link and his team were 
eventually successful in isolating the anticoagulant agent and finally proved that 
synthetic dicoumarol was identical to the naturally occurring chemical entity, in 1940. 
(Stahmann 1941) Work on several similar chemicals wielded more potent anti-
coagulants, and one of those new chemical entities, warfarin, was patented by Karl Link 
and first marketed as a rodenticide. Further studies investigated its properties as a 
therapeutic anti-coagulant and warfarin started being prescribed for heart attack 
sufferers in 1955 (Link 1959). 
 
 The synthesis of warfarin sodium involves stirring pure warfarin acid and 
sodium carbonate (1:1.6 molar ratio) in an absolute ethanol medium at a temperature of 
30 oC for two hours, with the isolation steps requiring a vacuum filtration and oven 
drying. Figure 4.1 describes the synthetic step (Ashkar 2004):  
 
 
Figure 4.1 Synthesis of warfarin sodium 
 
 
This synthesis was not selected for experimental studies due to the high cost of 
purchasing warfarin acid. Also, the stirring time is above what was desirable for this 
project.  
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4.1.2 – Nitisinone 
 
Nitisinone’s origin can be traced to the 1980’s when new research at Syngenta 
was put in place to find more potent herbicides, but its use as a weed killer was halted 
after it was found that nitisinone cause eye lesions to rats.  
 
It was subsequently found that it was an efficient drug in the treatment of 
tyrosinemia. The carriers of this rare hereditary disease are unable to process the amino 
acid tyrosine. If left untreated, tyrosinemia can lead to kidney and liver failure, mental 
retardation and eventual death. Until nitosinone was applied in its treatment, the 
primary course of action would be a liver transplant – with all the health implications 
that such a complicated procedure can carry (Santra and Baumann 2008; McKiernan 
2006; Lock et al 1998). 
 
 The synthesis of nitisinone involves the acylation of a solution of cyclohexan-
1,3-dione in dichloromethane with the acid chloride, adding triethylamine dropwise 
(molar ratio 1:1:1.3) for an hour at ambient temperature, as shown in Figure 4.2: 
 
 
Figure 4.2 Synthesis of nitisinone 
 
 Although the reaction in itself is relatively simple to be carried out, the product 
isolation is not trivial: it involves two consecutive strong acid washes and extractions to 
remove triethylamine and a subsequent rotary evaporation. A substantial amount of time 
is then needed in order to prepare samples for analysis, and that incompatible with the 
smooth running of a continuous seven day production campaign. For this reason 
nitosinone was deemed not to be a suitable candidate for this project.  
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4.1.3 – Tesmilifene 
 
Tesmilifene, a drug still in development, has shown promise as an antitumor 
agent. The mode of action is as yet unknown, but it has been proved that it enhances 
the activity of several classes of chemotherapy agents against cancers that are 
resistant to other drugs in patients with symptomatic metastases (Raghavan et al 
2005; Lednicer and  Mitscher 1999).  
 The last synthetic step is an alkylation. An acidic solution of p-benzylphenol is 
reacted with 2-chlorotriethylamine for 30 to 60 minutes, at 55 to 60 oC, as shown in 
Figure 4.3 (Brandes and Hermonat 1989): 
 
 
Figure 4.3 Synthesis of tesmilifene 
 
 The synthesis is relatively simple to carry out, but during the reaction two layers 
are formed. Similarly to the nitisinone product isolation, this involves two washes (the 
first one with sodium hydroxide and the second with hydrochloric acid) and a 
subsequent vacuum drying step. Thus, preparing samples for analysis is a labour 
intensive procedure that is not compatible with the running of a production campaign. 
The synthesis of tesmilifene was not pursued in this project due to this reason.  
 
4.1.4 – Acamprosate calcium 
 
In recent years there has been a drive towards finding effective drugs to control 
alcohol addiction. Homotaurine, an antagonist of γ-aminobutyric acid (the main 
inhibitory neurochemical which takes part in the regulation of excitability throughout 
the mammalian nervous systems), is thought to stabilize the brain’s chemical balance 
that is disrupted by the abuse of alcoholic substances. Acamprosate calcium, the 
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calcium salt of the n-acetyl derivative of homotaurine has the same therapeutic effects 
and helps maintaining abstinence by preventing relapse. It was approved by the FDA 
for human use in 2004 (Williams 2005; Watanabe 2002; Lednicer and  Mitscher 1999).  
 
 For this acylation calcium hydroxide, acetic acid and homotaurine are stirred in 
water until dissolution at a temperature of no more than 40 oC (molar ratio 1:2:2). A 
slight excess of acetic anhydride is then added and the solution is left to stir between 30 
and 40 oC for an hour. The solution is then concentrated under vacuum (Durlach 1982; 
Lednicer and  Mitscher 1999) Figure 4.4 shows the scheme of the reaction: 
 
 
 
Figure 4.4 Synthesis of acamprosate calcium 
 
 Acamprosate calcium is a very interesting molecule from the point of view of its 
therapeutic effects, and its synthesis and isolation is straightforward. It would be an 
ideal chemistry to include in this project, but the prohibitive cost of homotaurine 
excluded the possibility of studying this chemistry further. 
 
 
4.2 – Chemistries selected 
 
 
Five different chemistries were pre-selected for screening. The chemical 
products studied in batch belong to the cosmetics & toiletries (C&T) and the 
pharmaceutical markets and include a cyalume (bis(2,4,6-trichlorophenyl) oxalate), two 
fragrances (methyl diantylis and vanisal sodium) and two APIs (acetylsalicylic acid and 
paracetamol). 
 
The European pharmaceutical industry alone accounts for 19.2% of all business 
related R&D investments and represents around 3.5% of the total EU manufacturing 
value added. Despite being valued at circa €150 billion in 2007, having grown at a 
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median rate of 7% over the previous ten years, the pharmaceutical market in Europe 
accounted for less than a third of the total world pharmaceutical market in that year 
(EFPIA 2009). On the other hand, the European Union Cosmetics & Toiletry (C&T) 
market was valued at circa €62 billion in 2008. Accounting for 14.8% of this total, the 
market in the UK had grown by circa 10% from the previous year (COLIPA 2008). 
Figure 4.5 depicts the European Union C&T market and the relative importance of each 
continent in the world pharmaceutical market. 
 
In the following sections the fine chemicals and pharmaceutical compounds that 
were screened for this study are described in more detail. The synthesis of each studied 
compound was executed according to the literature and the results obtained from the 
batch experiments can directly be applied to the COBR. In order to perform the 
experiments in the batch OBR the available protocols had to be adapted and typical 
procedures used are described hereinafter, followed by the obtained results.  
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Figure 4.5 European  Union Cosmetics and Toiletries Market sales in 2006 and the World 
Pharmaceutical Market in 2007, in COLIPA 2008 and EFPIA 2009 (adapted) 
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4.2.1 – Bis(2,4,6-trichlorophenyl) oxalate 
 
This compound belongs to the family of cyalumes. Cyalumes are symmetrical 
diesters that when in contact with peroxides undergo a series of exothermal chemical 
reactions, producing carbon dioxide and light in the presence of a colorizing molecule. 
This class of molecules is the result of long years of research that started in the 1960’s, 
when scientists were trying to explain the chemiluminescence phenomenon. One such 
scientist was Edwin Chandross: when working at Bells Laboratories, he discovered the 
underlying mechanism behind this type of reaction. Currently the owner of more than 
60 patents (Sturchio 2005), he later found out that because he failed to patent his 
discovery he missed on a very profitable business. The company that patented the 
“Chemical Light Device” was the American Cyanamid Company (Zandt 1977), which 
benefited from Edwin Chandross’ work and took it one step further - Michael Rauhut 
tried to improve the efficiency of the chemiluminescent reaction by synthesizing a series 
of oxalate esters and was ultimately able to raise Edwin’s 1% quantum yield to 5% 
(Wilson 1999; Peters 2002). 
 
Nowadays, the lightstick business is a multimillion industry. It has found uses in 
the military, fire-fighters, police corps, in outdoors activities such as fishing, hiking and 
camping and even in our cars and homes. Its popularity is due to its durable and 
waterproof container that does not depend on batteries and does not create sparks, 
therefore being one of the most dependable and safe sources of light. Cytec Industries, 
the company that owns the Cyalume trademark, was worth circa €534M in March 2009 
(Fortune 2009). 
 
The chemical reaction that is used to produce bis(2,4,6-trichlorophenyl) oxalate 
is as shown in Figure 4.6: 
Cl
Cl
Cl
OH
Cl Cl
O O
Cl
Cl
Cl
O
Cl
Cl
Cl
O
O O
+2
2Et3N
+ 2Et3NH. Cl
2,4,6-Trichlorophenol oxalyl chloride Bis(2,4,6-trichlorophenyl)oxalate  
     
    Figure 4.6 Synthesis of bis(2,4,6-trichlorophenyl) oxalate 
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 The synthesis procedure described in literature is similar to the one described in 
the following section, with the exception that reflux is required for 20 minutes. 
Refluxing the solvent requires more equipment and makes the setup more complicated, 
which is a clear process disadvantage. The reported yield for this reaction is 60% 
(McCapra 2000; Jasperse 2007).  
 
 
4.2.1.a – Synthesis of bis(2,4,6-trichlorophenyl) oxalate 
 
 The procedure used is as follows: 
 
1. Weigh out 5.27 g of  trichlorophenol; transfer it to the batch OBR; 
2. Add 40 mL of  toluene and 3.70 mL triethylamine (using a syringe) and begin 
oscillation (ν = 2.0 sec-1; x0 = 40 mm); 
3. Cool the reactor to 5 °C using ice-water bath and add 1.30 mL of oxalyl 
chloride; 
4. Plug a hot water bath (Twater = 95°C) to the OBR for 10 minutes; 
5. Transfer the reaction product to an Erlenmeyer flask and chill it, using a ice-
water bath; 
6. Perform a vacuum filtration, using hexane; 
7. Dry the solid in the oven for two hours at 30°C; 
8. Wash the solid with purified water (the cyalume is insoluble, whereas the 
formed triethylamine hydrochloride is soluble in water); 
9. Filter the product using a vacuum apparatus and purified water; 
10. Oven-dry the solid (o/n, 30 °C) and weigh the samples. 
 
Due to the toxicity of the chemical compounds involved in this synthesis, it was not 
possible to take several samples along the reaction time. A 10 mL sample was taken at 
the end of the reaction and was isolated in the way previously described. 
 
 
 
62 
 
4.2.1.b – Results 
 
Due to the toxicity risk posed by all of the reactants used it was not possible to 
sample the reaction while it was occurring - the safety guidelines suggested that it was 
advisable to stop the reaction at a given time so that the product could be analyzed 
safely. Figure 4.7 shows the temperature profile inside the OBR after the oxalyl chloride 
was added to the solution, when the hot water bath was plugged to the reactor. The 
boiling point of the used solvent (toluene) is 110-111 oC. Refluxing the reaction 
mixture, as suggested in literature, indicates that the reaction should be performed at 
higher temperatures than those recorded in this experiment.  
 
 
 
Upon addition of oxalyl chloride the reaction progressed and the mixture inside 
the reactor changed within the first minute from orange to a brownish colour. The 
resulting precipitate became a pale yellow powder after the isolation steps. The obtained 
yield of 67% is superior to that described in literature (60%). 
 
Figure 4.7 Temperature profile inside the OBR 
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Figures 4.8 and 4.9 compare the IR spectrum obtained for the product sample 
with the IR spectrum published in literature. It is evident that they are similar, proving 
that the obtained product is indeed the cyalume. The band at 3435 cm-1 indicates the 
presence of the hydroxyl group, possibly from water residues left from the isolation 
procedure. Table 4.1 correlates the IR peaks from the spectrum with the molecular 
structure of the synthesised bis(2,4,6-trichlorophenyl) oxalate. 
 
 
 
 
 
 
Figure 4.8 IR spectrum of the synthesized Bis(2,4,6-trichlorophenyl) oxalate, KBr disc 
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Table 4.1 IR spectrum peaks and its molecular significance11 
 
Bond 
Experimental data 
peak (cm-1) 
Literature data 
peak (cm-1) 
 
Aromatic C-H 
 
3084.0 
 
3086 
Ester C=O 1786.3 1786 
Aromatic C-C 
1567.3 1568 
1447.4 1449 
Ether C-O  
1228.0 1229 
1110.4 1115 
 
                                                 
11 The reference IR bands and peaks are described in Morrison, R. and R. Boyd (1992). Organic 
Chemistry. New Jersey, Prentice-Hall. Literature peaks in National Institute of Advanced Industrial 
Science and Technology (Japan) 
Figure 4.9 IR spectrum for Bis(2,4,6-trichlorophenyl) oxalate, KBr disc. Source: 
National Institute of Advanced Industrial Science and Technology (Japan) 
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The results gathered for this set of experiments show that performing this 
synthesis in OBR would have a number of advantages over the method reported in the 
literature (Jasperse 2007). Not only was the reaction time faster than the 20 minutes 
cited, but also toluene refluxing was not needed to accelerate and complete the reaction. 
It is well-known that the superior mixing and heat-transfer capabilities of the OBR 
confer this reactor design a marked advantage over more traditional types of reactors. 
This means that less heat is delivered to the system and energy is saved, the risk of 
decomposing reactants or product is greatly reduced and the experimental apparatus is 
simplified.  
 
The aforementioned health and safety compliance issues prevented further 
studies on this chemical species from taking place. In conclusion, it would not be 
impossible to adapt this synthesis to the COBR, but this chemistry was not chosen for 
further studies in the COBR given the increased cost of adapting and implementing 
further safety procedures and equipment. 
 
 
4.2.2 – Methyl diantilis 
 
 The use of perfume and scented materials goes back thousands of years. The 
origin of the word “perfume” is associated with the burning of incense, one of the oldest 
rituals where aromatic materials played an important part (Latin: per fume). In every 
great world civilization references to perfumes and fragrances can be found – from the 
Sumerian to the Greek civilizations, the Egyptians and Romans, in all of these cultures 
perfume was an important part of life (Pybus 1999; Fortineau 2004). At the end of the 
19th century chemistry was replacing alchemy and the work on fragrances prompted 
Jean-François Houbigant to produce “Fougère Royale”, founding modern perfumery 
(Kraft et al 2000). Nowadays, the perfume industry is a relatively mature one and 
thousands of fragrances enter the composition of a myriad of different products. In the 
continuous search for new and attractive chemical compounds, organic chemists 
regularly synthesize new fragrances. 
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One such fragrance is 2-ethoxy-4-(methoxymethyl)phenol, more commonly 
known as methyl diantils. It was born out of the necessity of having a more powerful 
alternative to vanillin, but, unlike isoeugenol, one that wouldn’t lose its colour with 
time. Named after carnations (Dianthus caryophllus), Methyl Diantilis “has a sweet and 
creamy vanilla odour reminiscent of white chocolate” (Kraft et al 2000; Miles and 
Connell 2006) and its synthesis was patented by Givaudan Corporation, a leader in the 
flavours and fragrance industry (Ochsner 1987). The last step in the synthesis of methyl 
diantilis is the one studied in this project and is given in Figure 4.10: 
 
O
OH
OH
OH
O
O
OH
+
3-ethoxy-4-hydroxybenzyl alcohol Methyl Diantilis
amberslyst
50oC
 
 
Figure 4.10 Synthesis of methyl diantilis 
 
 
 The synthetic process for Methyl Diantylis described in literature (Miles and 
Connell 2006)  is very similar to the procedure described next, with the exception that 
the experiment was conducted under milder temperature conditions thus obviating the 
need for solvent refluxing.  
 
 
4.2.2.a – Synthesis of methyl diantilis 
 
 The procedure adapted for the OBR includes: 
 
1. Weigh out 3 g of Amberlyst-15 (a strongly acidic cation exchange resin) and 
wash 6 times with 10 ml of methanol. Transfer it to the batch OBR; 
2. Add 45 ml of methanol to the OBR. Start the oscillation (ν = 2.0 sec-1; x0 = 40 
mm); 
3. Add 3 g of 3-ethoxy-4-hydroxybenzyl alcohol (a small amount at a time) to the 
OBR; 
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4. Plug the  hot water bath (Twater = 62 oC) to the reactor for 15 minutes;  
5. Perform a vacuum filtration of the product, using methanol; 
6. Remove the solvent using a rotary evaporator under vacuum at 30 oC; 
7. Weigh the samples. 
 
The OBR oscillation had to be stopped for a few seconds each time a sample 
was taken from the reactor because the design of the particular OBR prevented on-line 
sampling. Each 10 ml sample was taken on regular intervals from step 4) in the 
procedure, using a small pipette. All samples were isolated as described in steps 5 to 6. 
 
 
4.2.2 – Results 
 
In line with what happened for bis(2,4,6-trichlorophenyl) oxalate, the synthesis 
of methyl diantilis was done with a simpler setup and was quicker to complete in the 
OBR than what is described in literature (Miles and Connell 2006) because the use of a 
refluxing apparatus was obviated.  
 
 As described in the procedure, a pre-treatment of the used catalyst by applying a 
methanol washing was necessary before the synthesis could be started, which 
transformed the previously crème amberlyst spheres to “dirty white”.  
 
Figure 4.11 displays the temperature profile of the reaction at sampling times 
and shows that the temperature inside the OBR remained very stable throughout the 
experiment, which was carried out without the need for refluxing the methanol. 
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A deep vanilla scent with carnation notes was evident even from the first sample 
taken, thus implying the presence of methyl diantilis. The peak data available by Miles 
and Connel (2006) for this chemical compound is the following: IR (neat) 
3427,2981,1606 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.87 (m, 2 H), 6.80 (dd, J =1.8, 
8.0 Hz, 1H), 5.89 (s, 2 H), 4.11 (q, J = 7.1 Hz, 2 H), 3.35 (s, 3 H), 1.43 (t, J = 7.2 Hz, 3 
H). Figures 4.12 to 4.23 show the IR and NMR spectra of the samples, which confirm 
the smell analysis and indicate that the reaction was completed within 8 minutes from 
the start, considerably faster than the 20 minutes reaction time described by Miles and 
Connel (2006). Notwithstanding, the data obtained for some of the samples suggest that 
the solvent elimination was not complete – as affirmed by Dr. Alan Boyd, of Heriot-
Watt University, the extra peaks reveal the presence of methanol that was not totally 
evaporated from the samples analyzed – and so the vacuum filtration should have been 
more thorough. The reaction time might indeed be shorter, but the methanol 
contamination of some of the samples prevents from drawing a more definite 
conclusion on this matter.  
 
After the isolation steps, the resulting end product was a pale yellow liquid with 
the characteristic vanilla and carnation odour of methyl diantilis. The identification of 
Figure 4.11 Temperature profile and sampling times for the methyl diantilis 
reaction. 
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the IR spectrum peaks for the sample where less solvent was found (sample 4) is 
described in Table 4.2. 
 
 
   Table 4.2 IR spectrum peaks/bands and its molecular significance1 
 
Bond Literature  
Peak/band (cm-1) 
Experimental (sample 4) 
Peak/band (cm-1) 
 
Aromatic O-H 
 
3427 
 
3367 
Aromatic C-H 2981 2945 
Aromatic C-C 1606 1604 
 
 
 
Figure 4.12 IR spectrum of the synthesised methyl diantilis, sample 1 
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Figure 4.13 1H 400Mhz NMR spectrum of the synthesised methyl diantilis, sample 1 
Figure 4.14 IR spectrum of the synthesised methyl diantilis, sample 2 
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Figure 4.15 1H 400Mhz NMR spectrum of the synthesised methyl diantilis, sample 2 
Figure 4.16 IR spectrum of the synthesised methyl diantilis, sample 3 
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Figure 4.18 IR spectrum of the synthesised methyl diantilis, sample 4 
Figure 4.17 1H 400Mhz NMR spectrum of the synthesised methyl diantilis, sample 3 
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Figure 4.19 1H 400Mhz NMR spectrum of the synthesised methyl diantilis, sample 4 
Figure 4.20 13C 100Mhz NMR spectrum of the synthesised methyl diantilis, sample 4 
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Figure 4.21 13C 100Mhz (depth) NMR spectrum of the synthesised methyl 
diantilis, sample 4 
Figure 4.22 IR spectrum of the synthesised methyl diantilis, sample 5 
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In summary, there are two main advantages of performing this reaction in OBR: 
it is faster and it is carried out at lower temperatures (energy is saved), which, in turn, 
makes the experimental apparatus simpler because there is no need to reflux the solvent. 
Once again it is proved that the more efficient mixing occurring in each of the OBR’s 
cells leads to better heat transfer and thus to faster reaction times than those observed 
for more traditional reactors 
 
The synthesis of this chemical compound was not pursued further in the COBR 
due in part to the high costs associated with the purchase of the catalyst, but more 
importantly the intrinsic need for its methanol pre-treatment which is more time 
consuming than what was foreseen. 
 
 
Figure 4.23 1H 400Mhz NMR spectrum of the synthesised Methyl Diantilis, sample 5 
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4.2.3 – Vanisal sodium 
 
 Vanilla is one of the most popular odours in the fragrance industry. Since the 
early 1990’s perfume makers have been incorporating it in their creations as a 
significant part of the odour note, and, more recently, Body Shop introduced a pure 
vanilla fragrance in the market (Fox 2005).  
 
But while in perfumes vanillin - the molecule that is normally used to evocate 
the smell of vanilla - is relatively stable, that does not occur in soap formulations. Due 
to the combination of light, heat and the basic conditions in soaps, vanillin and its 
derivatives undergo chemical reactions that rapidly transform them into polyphenols 
and other detergent products. The outcome of these events is the discolouring of soaps – 
from a light tone progressively to brown and eventually black; another consequence is 
the loss of foaming power (Vidal 2006; Turin 2007). 
 
The most common path to overcome this problem is to use more odour-potent 
chemical variations of vanillin (such as ethyl vanillin) in low enough concentration, use 
colouring agents or non-discolouring chemical alternatives to mask the aforementioned 
problems. This means that either the resulting soap cannot be clear or the soap does not 
have the desired scent properties. 
 
Flexitral Inc. was founded by Luca Turin - the “Emperor of Scent” - where he 
has had the opportunity to put to the test the highly controversial vibrational theory in 
the creation of new odour molecules. As opposed to the widely accepted lock-and-key 
concept defended by the shape theory, the vibrational theory defends that after fitting in 
the receptor site, the odour molecule must have a vibrational energy compatible with the 
different receptor’s energy levels so that electrons can travel through the molecule via 
inelastic electron tunnelling, thus triggering a signal transduction.  
 
This flavours and fragrances company has recently launched in the market two 
solutions to the aforementioned problem: vanisal and ethyl vanisal. The company 
claims that these two compounds, which are the product of the treatment of vanillin and 
ethyl vanillin with a sulfiting agent, do not suffer from discoloration when used in the 
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composition of soaps and retain the  much appreciated vanilla scent (O'Hare 2006; 
Brechbill 2007; Turin 2007). 
 
The reaction scheme to the production of vanisal sodium is as shown in Figure 
4.24: 
 
O
O
OH
NaHSO3
O
OH
OH SO3Na
+
vanillin vanisal sodium
H2O
60oC
 
            
Figure 4.24 Synthesis of vanisal sodium 
 
 
 According to the Flexitral patent, vanisal sodium can be prepared by mixing 
equimolar amounts of sodium hydrogen sulphite and vanillin in water, either at room 
temperature or at 50 to 60 oC. The reaction is complete when there is no undissolved 
vanillin, an indication that it has reacted to form the sulphite adduct. 
 
 
4.2.3.a – Synthesis of vanisal sodium 
 
 The following steps are followed in order to perform this synthesis: 
 
1) Transfer 35 mL of purified water to the batch OBR; 
2) Heat the reactor to 60 °C; Measure 3.86 g of vanillin and 7.2 mL of sodium 
hydrogen sulphite 40%. Transfer it to the batch OBR; 
3) Start the oscillation (ν = 2.0 sec-1; x0 = 40 mm) and mix for 10 minutes; 
4) Transfer the solution to a beaker and put it in the oven (35 °C, overnight) and 
weigh the samples. 
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4.2.3.b – Results 
 
For the experiments just 10 to 12 seconds were sufficient after the oscillation 
had started in the OBR for the mixture to become transparent, a clear indication that the 
reaction was complete. This suggests that the reaction can indeed progress at lower 
temperatures using an OBR, thus saving energy in the process. Although the patent that 
describes the method of manufacture of vanisal sodium (Turin 2007) does not mention 
reaction times, it was later stated in private correspondence with Luca Turin, the Chief 
Technical Officer of Flexitral, that the reaction times obtained in this set of experiments 
are “a little fast, but not wildly so” compared to the benchmark set by the company that 
markets this chemical entity. The mixing and heat transfer capabilities of the OBR were 
again tested and, as it had happened for the previously studies chemistries, this reactor 
design proved to be more efficient when compared to a more traditional design. 
 
Because the solution became transparent so quickly, only one sample was taken 
after 15 seconds of reaction time. The vanillin scent was evident and after the sample 
was oven-dried the resulting powder was analysed via NMR. A comparison between the 
spectrum obtained and the reference for pure vanillin (Figures 4.25 and 4.26) show a 
new peak at δ = 85.49 ppm, revealing the presence of a previously non-existent 
hydroxyl group attached to a tertiary carbon atom. This proves that the analysed sample 
was of vanisal sodium. The dried sample had a brittle white solid aspect, which was also 
consistent with the appearance of vanisal sodium as described by Luca Turin in the 
aforementioned private correspondence. 
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Figure 4.25 NMR spectrum of vanisal sodium 
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While being relevant for the valuable cosmetics and toiletries market, this was 
also the first chemical compound that gathered all the conditions and characteristics 
suitable for further studies in COBR, in order to prove its competence in the 
manufacture of fine chemicals. It was proved that the reaction is fast, economical and 
safe to operate from a health and safety point of view.  
 
 
 
 
 
Figure 4.26 Reference NMR spectrum of vanillin. Source: AIST, Japan 
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4.3.4 – Acetylsalicylic acid 
 
Acetylsalicylic acid, or aspirin as it is more commonly known, was born out of 
the necessity of having an alternative to salicylic acid, which, despite working well to 
relieve aches and pains, is hard to swallow and causes irritation to the digestive tract 
(Osborne 1998). When assigned to this task, Felix Hoffman of the Bayer 
pharmaceutical company came up with a method to make acetylsalicylic acid in 1897, 
two years after having started his research – a drug that not only was very efficient in 
the treatment of pain fever and inflammation, but also tasted better – and was granted a 
US patent to the process in 1900 (Hoffmann 1900; Henderson 2007)12.  
 
More than a century after the Bayer pharmaceutical company started selling 
aspirin, it still is one of the most widely used over-the-counter (OTC) drugs in the 
world. Nowadays over 100 billion tablets are produced and consumed annually, the 
equivalent to circa 35,000 tons. Despite facing hard competition coming from the 
generics manufacturers, aspirin is the 2nd top selling Bayer Consumer Health product, 
with sales close to €720M (BAYER 2009). With around 3500 scientific papers every 
year dedicated to it, aspirin is no longer regarded simply as a pain reliever or an anti-
inflammatory drug. Figure 4.27 shows the current usage trends for aspirin, and  recent 
studies claim that this drug might be used against colon, ovarian and breast cancer and 
also to improve brain function (Nordenberg 1999).  
                                                 
12 Despite this being the “official” version of Bayer AG., there is still some controversy to whom should 
the discovery and commercialization be credited. in Sneader, W. (2000). "The discovery of aspirin: a 
reappraisal." British Medical Journal 2000(321): 1591-1594.  
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The synthesis of acetylsalicylic acid, as idealized by Hoffmann, involves the 
acetylation of salicylic acid by acetic anhydride in an acidic medium, as showed in 
Figure 4.28: 
 
OH
COOH
O
CH3CH3
OO
COOH
O
CH3
O
O
CH3
OH+ +
salicilic acid acetic anhydride acetylsalicylic acid acetic acid
H+
95oC
 
 
Figure 4.28 The synthesis of acetylsalicilic acid 
 
  
 The traditional process of producing acetylsalicylic acid typically involves 
mixing a small stoichiometric excess of acetic anhydride with salicylic acid. This 
reaction is catalyzed by sulphuric acid and, and when performed at 85-90 oC takes 
between 20 minutes to 2 hours to complete (Kamlet 1956; McKetta and Cunningham 
1977; Metz 2002).  
 
  
 
 
   
14.10%
12.20%
13.80%
23.30%
37.60%
Other
Body ache
Headache
Arthritis
Heart disease
%
Figure 4.27 – Popular used for aspirin. Source: Bayer AG. (adapted) 
salicylic 
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4.2.4.a – Synthesis of acetylsalicylic acid 
  
The synthesis of acetylsalicylic acid involves the following steps:  
 
1. Weigh out 15 g of salicylic acid and transfer it to the batch OBR; 
2. Add 40 mL of acetic anhydride and 2 mL of concentrated sulphuric acid; 
3. Switch on the pre-heated water bath (Twater = 95 °C) to heat the OBR. Switch the 
oscillation (ν = 2.0 sec-1; x0 = 40 mm) on and mix for 10 minutes; 
4. Transfer the solution to an Erlenmeyer flask. Chill the mixture using an ice-
water bath and add 20 mL of purified water to decompose any excess acetic 
anhydride. Chill it until crystals of aspirin no longer form; mix it gently 
occasionally to decompose residual acetic anhydride. If an oily substance 
appears instead of a solid precipitate, reheat the solution until the substance 
disappears and cool it again.  
5. Perform a vacuum filtration of the product, using purified water to wash the 
crystals; 
6. Dry the crystals in the oven (30 °C; overnight); 
7. Determine the mass of the crude aspirin crystals. 
 
Each sample was taken at regular intervals from step 3) in the procedure, using a 
small pipette. All samples were purified in a similar fashion to the way described. 
 
 
4.2.4.b – Results  
 
Samples were taken from the reactor every 2 minutes for a total duration of 10 
minutes. Figure 4.29 shows the temperature profile of the reaction at sampling times. 
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The temperature measurements taken at sampling times indicate that the 
temperature inside the OBR rose steadily, quickly providing a suitable environment for 
the reaction to proceed rapidly. 
 
It was also observed that 10 seconds after the heated water-bath was connected 
to the reactor and the oscillation was started the solution was already clear, with no 
signs of salicylic acid solid aggregates, a sign that the mixing inside the OBR was 
efficient. In fact, the HPLC chromatograms (Figures 4.30 and 4.31) indicated that even 
in the first sample (taken 60 seconds after the reaction was started) there was little sign 
of reactants left or side products, as confirmed in Figure 4.30 – the existent peak at 10 
minutes of elution is relative to acetylsalicylic acid, as confirmed by the commercial 
sample chromatogram (Figure 4.32). The HPLC chromatograms for the remaining 
samples analysed can be found in the Appendix B. These results show that the reaction 
proceeded in the OBR at lower temperatures than those indicated to be necessary in the 
literature.  
Figure 4.29 Temperature profile for the acetylsalicylic acid samples 
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Figure 4.30 HLPC chromatogram of the synthesized acetylsalicylic acid, sample 1 
Figure 4.31 HLPC chromatogram of the synthesized acetylsalicylic acid, sample 2 
Figure 4.32 HLPC chromatogram of the pure aspirin sample 
86 
 
While it is known that higher temperature accelerates the reaction rate, the 
results show that the reaction can be undertaken under milder conditions. The product 
obtained after the crystallization and purification steps was in the form of fairly small 
crystals and white in colour.  
 
The results obtained from the experiments clearly indicate that the recommended 
reaction time was greatly reduced. The reaction can be considered to be completed in 
two minutes, which is shorter when compared with what is found in literature: typical 
reaction durations range from 30 minutes to 2 hours (Kamlet 1956; McKetta and 
Cunningham 1977). The OBR proved to be a superior alternative once again, this time 
in the manufacture of a popular API. The superior heat transfer and mixing capabilities 
of the OBR confer this design a definite advantage over others in the manufacture of 
both fine chemicals and pharmaceuticals. 
 
 In light of these findings and of the fact that this chemistry fulfils all the pre-
requisites set out in the beginning of the chapter, this was the second reaction to be 
chosen for further studies in COBR.  
 
 
4.2.5 – Paracetamol 
 
 When it was discovered - by mere dispensing accident - that acetanilide had 
anti-pyretic activity despite causing serious haemoglobin deactivation problems, 
researchers at Bayer synthesized phenacetin, a chemical derivative of acetanilide. 
However, due to its damaging effects in the kidneys of long-term patients, phenacetin 
had to be replaced by an alternative with fewer side effects. It was in 1893 that Joseph 
von Mering, came up with such drug: paracetamol. Unfortunately, having proved its 
anti-pyretic and pain-relieving properties this new molecule was put on hold for nearly 
half a century, when von Mering wrongly affirmed that it had the same side-effects as 
acetanilide13 (Ellis 1998). 
 
                                                 
13 It is currently believed that the side effects that von Mering observed were due to an impurity, 4-
aminophenol in Brown, T., A. T. Dronsfield, et al (2005). "Pain relief: from coal tar to paracetamol." 
Education in Chemistry 42: 102. 
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 By 1946 Bernard Brodie and Julius Axelrod were given a grant to investigate the 
effects observed by von Mering and discovered that acetanilide was indeed associated 
with methemoglobinemia and its therapeutic properties derived from paracetamol, to 
which it was metabolized in the human body (Brodie and Axelrod 1948). As a result 
they advocated the use of paracetamol to reduce pain and fever in patients and by 1955 
paracetamol was first marketed in the USA by McNeil Laboratories, under the name 
Tylenol Elixir (Brown et al 2005). 
 
 Since then paracetamol has become one of the most widely used drugs in the 
world. The world paracetamol market is worth circa 800 million Euros, equating to 
circa 160 thousand tonnes produced worldwide (Chassany 2008). In the UK alone there 
are over 90 different drugs brands with paracetamol in its composition and the most 
popular of them all, Anadin, is worth over 65 million Euros, selling 27 million packs 
every year (ANADIN 2006; Naish 2008). 
 
 The synthesis of paracetamol involves the reaction of acetic anhydride with 4-
aminophenol in aqueous medium (Figure 4.33): 
 
    
OH NH2
O
O O OH N
H
CH3
O
+
4-aminophenol acetic anhydride paracetamol
H+, H2O
95oC
 
 
Figure 4.33 The synthesis of paracetamol 
 
  
 In the traditional process for the synthesis of paracetamol, p-aminophenol is 
mixed with a small stoichiometric excess of acetic anhydride in an aqueous medium at 
high temperature and in the presence of phosphoric acid, which acts as a catalyst. The 
benchmark reaction time is circa 20 minutes for laboratory scale synthesis, as described 
in literature (Pavia et al 1990), 
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4.2.5.a – Synthesis of Paracetamol 
 
1. Weigh 1.8 g of p-aminophenol; transfer it to the batch  OBR; 
2. Add 30 g of pure water and 2 ml of phosphoric acid. Mix it until the amine has 
been dissolved; 
3. Switch on the pre-heated water-bath (Twater = 80 oC) to heat the OBR and 
carefully add 2.4 mL of acetic anhydride to the OBR; 
4. Mix the solution for 10 minutes (ν = 2.0 sec-1; x0 = 40 mm) and transfer the 
solution to a flask;  
5. Chill the mixture in an ice-water bath; 
6. Perform a vacuum filtration of the mixture, washing the flask with purified 
water;  
7. Oven-dry the produced crystals (30 °C; 2h); 
8. Determine the mass of the crude paracetamol crystals. 
 
Each sample was taken with regular intervals from step 4) in the procedure, 
using a small pipette. All samples were purified according to the protocol. 
 
  
4.2.5.b – Results 
 
Samples were taken from the reactor regularly for a total duration of 6 minutes. 
Figure 4.34 illustrates the temperature profile at the sampling times. It shows that the 
temperature rise in the OBR was quick, providing the required heat for the reaction to 
progress. 
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The HPLC data revealed that the reaction was considered complete well before 
the reaction time cited in literature, and the reaction progressed fast even though it was 
performed at lower temperatures. The amine was dissolved 30 seconds after the 
oscillation was started and the last sample was taken at the end of 6 minutes of reaction, 
at which point the low volume left inside the OBR meant that it was not feasible to take 
more samples from the reactor. The peak found in each of the chromatograms with an 
elution time of 7.5 minutes (Figures 4.35 and 4.36) refers to acetaminophen, which is 
identical to the peak found for the pure chemical compound (Figure 4.37). The HPLC 
chromatograms for the remaining samples analysed can be found in the Appendix C. 
 
 
 
 
 
 
 
 
Figure 4.34 Temperature profile for the paracetamol samples 
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Figure 4.36 HLPC chromatogram of the synthesized paracetamol, sample 2 
Figure 4.37 HLPC chromatogram of the pure paracetamol sample 
Figure 4.35 HLPC chromatogram of the synthesized paracetamol, sample 1 
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In line with the findings for the acetylsalicylic acid experiments, the temperature 
profile and chromatograms suggest that the reaction can be carried out under milder 
conditions, given the short reaction times. The end product was in the shape of large 
white crystals (0.5-1 cm).  
 
 This was the third chosen chemistry to be studied in COBR. Paracetamol is one 
of the most common anti-inflammatory drugs in the world and, in tune with what 
happens for acetylsalicylic acid and vanisal sodium, it complies with all the selection 
criteria. 
 
The OBR proved to be a better alternative to the STR in each of the five 
chemistries studied. The constant pattern of eddie formation and cessation inside each 
cell of the OBR increase the probability of different particles to collide and react with 
each other. This translates into better mixing and heat transfer capabilities and allows 
for faster reaction times, even at lower process temperatures, as it was proven in the 
experiments described in the previous sections. A finer control of process variables, 
such as reaction temperature, particle morphology and even particle size modulation can 
be achieved – this is a significant OBR advantage over the STR that has to be taken in 
consideration by pharmaceutical and fine chemical companies trying to optimize their 
manufacturing processes. Table 4.3 compares the chemistries that underwent screening, 
summarizing which selection criteria each chemical reaction fulfils. On this basis, the 
chosen chemical compounds to be studied further in COBR were vanisal sodium, 
acetylsalicylic acid and paracetamol.  
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Table 4.3 Selection criteria fulfilled by the screened chemistries 
  
Bis(2,4,6-
trichlorophenyl) 
Oxalate 
 
Methyl 
Diantylis 
 
Vanisal 
Sodium 
 
Acetylsalicylic 
Acid 
 
Paracetamol 
 
Chemistry type 
 
FC 
 
FC 
 
FC 
 
API 
 
API 
Relevance      
Reaction time      
Cost      
Safety      
Key: FC – fine chemical; API – active pharmaceutical ingredient 
 
 
4.3 – Summary 
 
This chapter described the experimental results for the five different chemical 
entities that were screened. While the results obtained were positive with regard to 
reaction conditions, reaction times and product yields, the chemical entities to be 
subjected to further studies in COBR were narrowed down to three. All the selection 
criteria were fullfiled for the following chemistries: vanisal sodium, acetylsalicylic acid 
and paracetamol. 
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CHAPTER 5 
COBR EXPERIMENTS 
 
 
Argument is conclusive, but it does not remove doubt,  
so that the mind may rest in the sure knowledge of the truth,  
unless it finds it by the method of experiment.  
 
Roger Bacon, philosopher 
 
 
From the results obtained in the screening experiments it was determined that 
three chemistries, namely vanisal sodium, acetylsalicylic acid and paracetamol, were 
better suited for the purpose of studying the robustness and adaptability of the COBR, 
as well as the degree of cross-contamination. One of advantages of this mixing 
technology is that the results obtained from the batch OBR can directly be applied to the 
continuous operation because the scale up is linear. This means that the procedure, the 
operation and the analysis done at the screening stage are transferable here with 
minimal adaptations.  
 
Critical product and chemical process attributes, such as reaction times, particle 
size, morphology and campaign waste and turnaround times were given special 
relevance in the COBR experiments due to the importance of these aspects to the fine 
chemical and pharmaceutical industries. The experimental procedure and the results 
gathered for each of these are described in the following sections, preceded by mixing 
and residence time distribution (RTD) considerations for the used COBR. 
 
 
5.1 – Mixing and Residence Time Distribution 
 
Inside a COBR with no oscillation being applied a particle is subjected to three 
different forces: gravity, buoyancy and fluid drag. Therefore, the particle will 
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continuously accelerate downwards until the fluid drag force balances out the force of 
gravity, at which point it will fall at a constant velocity until it is deposited in the COBR 
wall (Levenspiel and Kunii 1991; Coker and Ludwig 2007). This constant velocity is 
also referred to as terminal velocity and can be derived in the following way:  
 
 0=−−= dbg FFFdt
dum  (5.1) 
 
where Fg is the force of gravity, Fb the buoyant force and Fd the drag force (N). Thus: 
 
 dbg FFF =−  (5.2) 
 
and 
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Substitution of equations 5.3 and 5.4 in 5.2 gives: 
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where ut is the terminal velocity (m.s-1), g the gravitational acceleration (m.s-2), ρp and 
ρl  the densities of the particle and of the fluid, respectively (kg.m-3), m the mass of the 
particle (kg), Ap the projected area of the particle (m2) and CD the drag coefficient. If 
the shape of the particle is considered to be spherical with a diameter D, then the 
particle mass is 
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and its projected area is 
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Substitution of equations 5.8 and 5.7 into equation 5.6 gives: 
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In order for particles to remain in suspension, other forces must come into play. 
The combined velocity imposed in the COBR by the net flow and the oscillatory motion 
must then be equal or greater than the terminal velocity of the particles, if it is to remain 
in suspension in the fluid. 
 
Applying oscillatory motion to a fluid in a baffled tube results in the 
improvement of mixing conditions of the system. Whereas mixing is independent of net 
flow in a COBR, this does not happen in a traditional PFR, where a minimum Reynolds 
number has to be maintained for good mixing to occur. One of the advantages of the 
COBR is that it allows for a small net flow type of operation while maintaining good 
mixing conditions. It was shown by Harvey and colleagues (2001) that an increase of  
Ren will not significantly impact on the rheology and residence time distribution of the 
system.  
 
 Good mixing was achieved in the COBR during the three week-long campaigns 
due to the imposition of a high oscillatory Reynolds number (Reo) coupled with a low 
flow rate. This ensured that good radial mixing and narrow RTD was achieved, 
guaranteeing that all the non-dissolved particles remained in suspension, thus 
preventing deposition and, in a worst-case scenario, the clogging of the COBR. The 
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utilization of a low net flow also allows for savings to be made in expensive raw 
materials. A comparison between the terminal velocity and the mixing velocity in the 
COBR for the aspirin and paracetamol campaigns can be found in Table 5.1. vanisal 
sodium’s product is in the form of very fine particles and can thus be easily suspended 
in solution in the COBR. 
 
Table 5.1 Comparison between terminal velocity (ut) and mixing velocity (um) for the 
aspirin and paracetamol campaigns 
 
 Aspirin Paracetamol 
 
ρp (kg.m-3) 
 
1.350 
 
1.263 
ρl (kg.m-3) 1.108 1.046 
D (m*10-6)14 400 425 
CD 15 0.8 0.8 
ut (m.s-1) 0.0378 0.0379 
x0 (m) 0.02 0.02 
f (s-1) 2 2 
uo (m.s-1) 0.04 0.04 
un  (m.s-1) 0.0002 0.0019 
um (m.s-1) 0.0402 0.0419 
 
 
 It is evident that um was superior to ut for both cases. This ensured good mixing 
conditions in the COBR and that the particles remained in suspension for the duration of 
the campaigns. 
 
 
                                                 
14 These are literature values taken from crystallization experiments for the studies chemistries (in 
Cambeiro, L. et al (2006). "Crystallization of Aspirin Crystals in Polar and Non Polar Solvents in the 
Presence of Surfactants: An Experimental Approach to Control Size and Shape of Crystals." The New 
Jersey Governor's School of Engineering and Technology Research Journal. and Granberg, R. A. and Å. 
C. Rasmuson (2005). "Crystal growth rates of paracetamol in mixtures of water + acetone + toluene." 
Particle Technology and Fluidization 59(1): 2441 - 2456. 
15 Value taken from Hölzera, A. and M. Sommerfeld (2007). "New simple correlation formula for the 
drag coefficient of non-spherical particles " Powder Technology 184(3): 361-365. 
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5.2 – Vanisal Sodium 
  
 
Vanisal sodium was the first chemical compound to be produced in the purpose-
built COBR. The experimental method is described next. This is followed by the results 
gathered during a week-long run. 
 
 
5.2.1 – Experimental Method 
 
 
The operational procedure is as follows: 
 
 
1) The COBR was flooded with purified water; 
2) The COBR and the OBR feeder were heated up to 60 oC and oscillation was 
started (ν = 2.0 sec-1; x0 = 40 mm); 
3) 143 mL of sodium hydrogen sulphite 40% was measured; 
4) 77.1 g of vanillin was weighted and 700 mL of purified water was measured. 
These were transferred to the OBR and mixed until vanillin was dissolved; 
5) The COBR was fed with the contents of the OBR feeder along with the sodium 
hydrogen sulphite via the second feeder line; 
6) The feed rate of the contents to the COBR was checked at a flowrate of 2 
mL.min-1 and temperature readings were taken; 
7) Samples were taken and dried for analysis; 
8) Steps 3 to 7 were repeated 27 times. 
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Figure 5.1 Temperature measurements during the vanisal sodium reaction 
5.2.2 – Results  
 
Vanisal sodium was synthesized in a continuous fashion using the purpose-built 
COBR for the duration of seven days, 24 hours a day. The temperature measurements 
from the four thermocouples during the reaction are shown in Figure 5.1 and constant 
temperatures are seen along the COBR. This indicates that the environment within the 
COBR is highly consistent and reliable for the reaction, promoting the synthesis of a 
highly homogenous and uniform product throughout the campaign. Samples were taken 
regularly from the sampling valves and analyzed and the amount of vanisal sodium 
produced was plotted against time.  
 
 
 
 
Figure 5.2 displays the data from the sample locations S1 and S4 along the 
COBR as shown in Figure 3.4. It is clear that there is a time delay in the product at the 
start from the furthest sample port in comparison to that at the closest location from the 
feed line. The production of vanisal sodium was consistent during the whole the 
operation, in light of the stability of the temperature readings and concentration data. 
The samples recovered and dried all had the same brittle white solid appearance, which 
was consistent with both the sample recovered and dried in the OBR experiment (see 
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Chapter 4) and the description given by Luca Turin in the private correspondence 
maintained. 
 
 
The purity of the product was assessed using both NMR spectroscopy and 
HPLC over 54 samples, with 99.92% and 99.95% purity of vanisal sodium, 
respectively. The calculated average was 99.94%, which demonstrates the robustness of 
both analytical methods and the high product purity obtained in this campaign. The 
percent weight yield, calculated as the ratio between the actual yield over the theoretical 
yield (Kotz et al 2009), averaged 91.4% over the analysed samples. 
 
The cleaning of the COBR started after the production run had been completed, 
so that cross-contamination could be assessed and the second campaign could be 
started. A cleaning-in-place (CIP) procedure was used, as explained previously in 
Chapter 2. As this is the first time that the cleaning process and procedure in a COBR is 
reported, two dimensionless groups are introduced that are relevant to the protocol: the 
cleaning index and the wash index.  
 
Figure 5.2 Concentration profile for the vanisal sodium production run 
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In order to assess the cleaning intensity of a cleaning process, it is useful to 
employ the cleaning index (Ψ), which is defined as the ratio between the net flow 
Reynolds numbers and the oscillatory Reynolds numbers used in both the cleaning 
(Rec) and the operation (Reop) periods. This ratio allows for a comparison to be made 
between the various cleaning procedures that took place during this project. It also 
allows for future comparisons to be made, if continuous oscillatory reactors are tested 
with different chemistries or operating conditions: 
  
 
O
op
O
c
Re
Re
Re
Re
=Ψ  (5.10) 
 
 
When the same oscillation conditions (Reo) were used, as in this campaign, the 
cleaning index is defined in this case as: 
 
 
op
c
Re
Re
=Ψ  (5.11) 
 
An important measure of the effectiveness of a cleaning procedure is the amount 
of waste produced during this operation. More specifically, it is of interest to compare 
the volume of the used chemical reactor with the volume of the waste generated. This 
can be studied and understood using the wash index (Ω), which is defined as the ratio 
between the washing volume (Vw) and the reactor volume (Vr): 
 
 
r
w
V
V
=Ω  (5.12) 
 
 
The cleaning procedure was defined having in account previous experience and 
advice from the pharmaceutical industry (Norton 2009). As such, the cleaning operation 
was performed by continuously pumping tap water (measured pH = 7.3) in the COBR  
(60 °C, ~0.5 L min-1), immediately followed by an industrial “free rinsing” cleaning 
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solution (Liquinox - Solujet, 1% solution), and lastly the USP grade water at room 
temperature. The oscillation frequency and amplitude were 2 Hz and 40 mm, 
respectively and the cleaning index was 228. Four samples per minute were taken from 
the COBR during the cleaning phase and were analysed using the HPLC method 
previously described. Figure 5.3 shows the remaining concentration of vanisal sodium 
during the washing process in the vertical axis, while the volume of washing liquids 
employed is the horizontal axis. This volume is also related to the time of cleaning 
liquids used as the horizontal axis in Figure 5.4. The dotted line in Figure 5.3 denotes 
the calculated maximum residual level of vanisal sodium (0.026 mg.mL-1) allowable 
when the COBR is changed over to produce aspirin, in accordance to the limits set by 
the International Pharmacopeia (2008), including a 100-fold safety factor, as shown: 
 
100
)aspirinin impurity  Max.C(C
limit sodium Vanisal COBRin asprin min COBRin asprin min 
×−
=           (5.13) 
 
Maximum impurities level in aspirin (IP) = 1% 
Minimum expected quantity of aspirin in COBR = 265 mg ml-1 
 
 It is evident that the COBR was clean well before the cleaning procedure had 
been completed. The wash index was 5.18, meaning that a total 10.8 L of washing 
liquids was used until the reactor was clean. To further prove the effectiveness of the 
cleaning procedure, the reactor was disassembled at ports V3 and V4 (possible dead 
legs due to valve design) and visually inspected for solid vanisal sodium residues. No 
residues were found at those locations, confirming that the reactor was clean.  
 
The loss of product, which is defined in this case as the ratio of the amount of 
vanisal sodium lost in the cleaning over the total vanisal sodium produced, was 0.001%. 
This is on a substantially lower level than the industry norm of 0.1-0.2% (Norton 2009). 
This cleaning procedure proved to be complete and efficient and, with that in mind, the 
same method was applied in the end of each of the following productions (Sections 
5.2.2 and 5.2.3). The time used in cleaning is considerably shorter than the total 
operation time, circa 0.28% of the total running time. 
 
 
102 
 
 
 
 
Figure 5.3 Washing data for vanisal sodium 
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Samples from ports S1 and S2 were taken during the cleaning process and 
quenched for analysis. The kinetics of the cleaning process were assessed from the 
washing data gathered from the samples and are shown in Figure 5.4 by plotting -
ln(C/C0) against time, where C is the concentration of the studied chemical species, 
vanisal sodium in this case, at a given time t (mg mL-1) and C0 the concentration of that 
chemical species at the start of washing (mg mL-1). The linearity of the fits in Figure 5.4 
confirms first-order kinetics for the washing process in the COBR, with an averaged 
rate constant of 0.0046 s-1 and t1/2 of 150 s.  It should be noted that the process of 
washing using water or detergent may not involve chemical reactions, the reaction 
kinetics adopted here is a reasonable means to study the washing process. 
   
 
Our data are in line with several other studies involving tubular equipment 
where cleaning was described as a first-order kinetics (Jennings et al 1957; Bourne and 
Jennings 1963; Karlsson et al 1998; Cabero et al 1999; Lelievre et al 2002).  
Figure 5.4 First order kinetics plot for vanisal sodium cleaning data 
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5.3 – Acetylsalicylic Acid 
 
 
The synthesis and crystallization of aspirin was carried out for a period of 7 
days, 24 hours a day. In the next section the experimental procedure is described, 
followed by the results obtained for the production campaign, including the cleaning 
phase. The kinetics of the reaction were also studied and the results are presented. 
 
 
5.3.1 – Experimental Method 
 
The experimental procedure used in this campaign includes: 
 
1) The COBR was flooded with acetic anhydride and the first 4 sections were 
heated up to 60 oC. The COBR oscillation was started (ν = 2.0 sec-1; x0 = 40 
mm); 
2) 263.1 g of salicylic acid was weighted. It was then transfered to the OBR feeder, 
previously heated up to 90oC. 700 mL of acetic anhydride were added; 
3) The COBR was fed with the contents of the OBR feeder, along with sulphuric 
acid via the second feed line; 
4) The feed rate of the contents to the COBR was checked at a flowrate of 2 
mL.min-1 and temperature readings were taken; 
5) A sample was taken for analysis; 
6) Steps 2 to 5 were repeated 27 times. 
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5.3.2 – Results 
 
In this production process the reaction takes place first, which is then followed 
by crystallization. It was therefore necessary to create a controlled temperature decrease 
along the COBR for the crystallization to take place, as it is shown in Figure 5.5. It is 
evident that during the week-long synthesis the temperature measured at each of the 
four thermocouples was stable and consistent.  
 
 
The amount of acetylsalicylic acid produced as a function of time is plotted in 
Figure 5.6 and once again it is visible that the production of aspirin is consistent over 
the course of the process. The purity of the product analyzed by HPLC was 99.57% 
over 54 samples. The operational consistency of the COBR goes in line with what was 
found for the production of vanisal sodium. The average yield over the 54 samples was 
77.4%, which is higher than that the 75% indicated in literature even though the 
concentration used in this work is lower than that found in literature (Kamlet 1956), as 
shown in Table 5.2. 
 
 
 
 
Figure 5.5  Temperature measurements during the acetylsalicylic acid 
production run reaction 
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Table 5.2 Experimental conditions and results for this work 
 and in the literature (Kamlet 1956) 
 
 Concentration of limiting 
reactant (Salicylic acid)  
(g.L-1) 
Temperature 
of Reaction 
(oC) 
Product 
Concentration 
(g.L-1) 
Percent 
Yield 
(%) 
 
Kamlet 
(1956) 
 
661.3 
 
 
90-92 
 
 
646.5 
 
 
75 
 
This work 263.1 90 268.5 77.4 
 
 
The polymorphism of aspirin has been a subject of controversy in recent times. 
While some authors claim that there is a second form of the acetylsalicylic acid crystal 
(classified as form II) in addition to form I, others doubt of its existence (Vishweshwar 
et al 2005; Amato 2007; Bond  et al 2007). Nevertheless, the XRD results in Figure 5.7 
confirm that the synthesized acetylsalicylic acid is of the form I, which is consistent 
with what is found in literature (Cambeiro et al 2006). The SEM images taken from the 
samples at the location S4 in the COBR are given in Figure 5.8.a for different times of 
operation. The obtained crystals of aspirin are all of the plate-type form, which again 
Figure 5.6 Acetylsalicylic acid produced continuously in the COBR 
107 
 
shows the consistency of the product during the week-long run. These crystals are 
comparable to the ones obtained by Cambeiro et al (2006) shown in Figure 5.8.b 
 
Figure 5.7 a) XRD results for the produced acetylsalicylic acid; b) XRD results for 
acetylsalicylic acid (form I) in Huang et al (2005) 
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The reaction kinetics between salicylic acid and acetic anhydride in the COBR 
was studied. This was done by following the concentration of salicylic acid during the 
reaction. Samples were taken at each of the sampling ports in the COBR, immediately 
quenched, analyzed using HPLC and averaged over the number of samples at each site. 
The concentration of salicylic acid as a function of time was then plotted and used to 
confirm the order of the reaction and evaluate the rate constant of the reaction. Figure 
5.9 shows ( 0
11
SASA CC
−
) against the time of reaction, where CSA0 and CSA are the 
 
Figure 5.8 a) SEM images of produced acetylsalicylic acid crystals; b) Plate shaped 
acetylsalicylic acid crystals, in Cambeiro et al (2006) 
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concentration of salicylic acid at the start and at anytime during the reaction. The 
concurrence between the results and the linear regression indicates that the reaction 
follows a second order kinetics with a rate constant of 0.029 L.g-1.s-1.  
 
 
Given that the cleaning procedure used for the vanisal sodium run was effective, 
the same technique was employed for the acetylsalicylic acid. Tap water at 60 oC was 
first pumped into the COBR, followed by a Liquinox - Solujet, 1% solution, and finally 
by the USP grade water, one immediately after the next. The same values of oscillation 
frequency and amplitude were also used during the cleaning.  
 
It is widely accepted that higher production and cleaning standards are required 
for pharmaceutical and biochemical products than for the fine chemical counterparts. 
Yet, there is no published guideline or information on how much higher it should be. 
That was the reason behind the higher cleaning index used for acetylsalicylic acid, 336, 
which is 1.5x higher than that used for vanisal sodium. Four samples per minute were 
taken during the cleaning cycle and analyzed. The results are shown in Figure 5.10, 
where the dotted line indicates the calculated maximum contamination level for 
Figure 5.9 Second order plot for the reaction between salicylic acid and acetic 
anhydride at 90 oC 
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cleaning validation purposes in the manufacture of paracetamol (2008), which was the 
next API selected for production in the COBR after this cleaning process. The 
maximum amount of residual acetylsalicylic acid (BL2) allowed in the COBR was 
calculated using the following expression developed by Leblanc (2000): 
 
SF1000000
API of dosedaily  minimum
API of dosedaily  minimum  BL
B
A
2 ××





=   (5.14) 
 
where BL2 is the limit of the target residue (in this case, the target residue is the bulk 
active APIA) in any finished drug product in which the residue may ultimately be found, 
APIA  is  the bulk active A, APIB is the bulk active B and SF is the Safety Factor (= 
0.001). In this case, this calculated value was 0.113 mg mL-1. Similar to what had 
happened with the vanisal sodium’s case, the COBR was cleaned after the washing was 
completed. The loss of product due to the cleaning process amounted to 0.005% of the 
total amount of product. This is again lower than the industry norm of 0.1-0.2% (Norton 
2009). The swab sample test was carried out at the V3 location in the COBR (see Figure 
3.4 in Chapter 3) according to the method developed by Nozal et al (2000) and is also 
presented in Figure 5.10 (). It is noticeable that the degree of contamination detected 
in the swab sample is well below the threshold. The result confirms that the cleaning of 
the reactor was effective. The wash index is 5.07 when the reactor is cleaned, which 
equates to 10.6 L of liquid waste. The amount of time used for cleaning is much smaller 
than the corresponding total operation time, only circa 0.19%. The reactor was once 
again disassembled and visually inspected for residues in sample ports V3 and V4. No 
residues were found at these locations, another indication that the cleaning procedure 
was effective. 
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Figure 5.10 Washing data for aspirin 
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The kinetics of the cleaning process for the acetylsalicylic acid run was also 
evaluated, and a plot of -ln(C/C0) against time is shown in Figure 5.11. The first-order 
kinetics are well suited to describe the cleaning process, which is in line with what was 
found for the vanisal sodium case. The mean rate constant is 0.006 s-1. As a result of the 
higher cleaning index used when compared to the one used in the vanisal sodium 
cleaning procedure, a higher rate constant was expected for aspirin cleaning 
(kaspirin/kvanisal sodium = 1.3). This indicates that at identical oscillation conditions, the rate 
constants for the cleaning of the COBR depend on the cleaning intensity that is 
regulated by the net flow, as suggested previously by Bird et al (1991). This implies that 
the washing process is mainly a physical process, in which mixing plays an important 
part.  
 
 
 
 
 
Figure 5.11 First-order kinetics plot for aspirin cleaning data 
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5.4 – Paracetamol 
 
The synthesis and crystallization of paracetamol was the next and final 
campaign in this PhD project. A continuous production and subsequent cleaning process 
of the COBR was carried out and the results are shown below, after the description of 
the experimental method.  
 
A first attempt of carrying out the synthesis and crystallization campaign of 
paracetamol with the COBR in a vertical layout and at a flowrate of 2.0 mL min-1 
(equivalent conditions to the aspirin campaign) proved to be unsuccessful, as crystals 
started accumulating around the PFA baffles situated just before P2 (see Figure 3.4). As 
the crystals accumulated, mixing on the subsequent sections was less and less efficient 
and eventually the pipe was blocked. This was probably due to the differential in 
pressure in the system - the top sections of the COBR were at a height of 2.80 m, 
making it difficult for the pump used to move all the fluid inside the reactor at a 
constant speed throughout the system. Thus, the fluid at the top sections was mixed 
poorly and the crystals that were being formed at those locations had more probability 
of interacting with the baffle surface. These conditions led to the continuous adherence 
of crystals to the baffle and the eventual blocking of that pipe section. The campaign 
had to be aborted and in light of these findings the COBR was re-orientated horizontally 
and the flowrate of the system was increased.   
 
 
5.4.1 – Experimental Method 
 
 For this campaign, the following steps were used: 
 
1) The COBR was flooded with purified water; 
2) The reactor was heated up to 80 oC (4 first sections), the OBR feeder was heated 
up to 90 oC and oscillation was started (ν = 2.0 sec-1; x0 = 40 mm); 
3) 48 g of p-aminophenol was weighted, 53.33 mL of phosphoric acid, 64 mL of 
acetic anhydride and 800 mL of purified water were measured; 
4) The purified water, p-aminophenol and phosphoric acid were transferred to the 
OBR feeder; 
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5) The COBR was fed with the contents of the OBR after all the amine was 
dissolved, along with the acetic anhydride via the second feed line; 
6) Feed flowrate of the contents to the COBR was kept at 20 mL min-1  and 
temperature readings were taken; 
7) A sample was taken for analysis; 
8) Steps 3 to 7 were repeated 128 times. 
 
5.4.2 – Results 
Paracetamol was synthesized and crystallized in the COBR with the same 
oscillation conditions used for the aspirin campaign and once again a constant 
temperature profile is required in the process. In Figure 5.6 it is apparent that the 
reaction and subsequent crystallization of aspirin was finished when the solution 
reached the first sampling port. In the paracetamol run, the flow rate of the reactants 
was increased by 10 fold to take that result in consideration. On one hand, this allows 
more concentration data to be obtained, showing the profile of paracetamol generating; 
on the other hand, this means that either the amount of starting materials required for 
the reaction is increased accordingly, or the overall running time is reduced for the same 
amount of material. In order to keep the project on budget the latter was the only option, 
i.e. the campaign was reduced from the 7 days initially planned to 4 days, 24 hours a 
day. 
 
In this run the COBR was operated horizontally in order to demonstrate the 
versatility of the system. Both reaction and crystallization were performed in this 
campaign and the variable temperature profile is used. Figure 5.12 shows the 
temperature profiles inside the COBR. The gathered data is once again in line with the 
previous experimental results, and very stable temperatures were achieved in the 
COBR. 
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Samples were taken from the various ports along the COBR and the amount of 
paracetamol produced along the run was determined. The results are shown in Figure 
5.13 and once again the data for each sample port was consistent. The product samples 
were analyzed using HPLC and the averaged purity was 99.63% over 55 samples. The 
Figure 5.12 Temperature measurements for the paracetamol production run 
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Figure 5.13 Concentration profile of the produced paracetamol 
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average yield obtained for this campaign was 79%, which is higher than that found for 
literature (circa 73%) even though the used feed concentration in this production run is 
lower (Schulman et al 1975), as shown in Table 5.3. 
 
Table 5.3 Experimental conditions and results for this work and in literature (Schulman, 
Baron et al 1975) 
 
 Concentration of limiting 
reactant (4-Amiphenol)  
(g.L-1) 
Temperature 
of Reaction 
(oC) 
Product 
Concentration 
(g.L-1) 
Percent 
Yield 
(%) 
 
Schulmann 
et al (1956) 
 
147.2 
 
 
85-90 
 
 
148.6 
 
 
72.8 
 
This work 52.3 80 58.6 79.4 
 
 
    
Crystals were taken from the PV sampling port (Figure 3.4) at different times of 
COBR operation and the XRD data presented in Figures 5.14 and 5.15 show that 
crystals are monoclinic (form I) (Yamamura and Momose 2003). The crystals were also 
imaged using SEM at 30x and 200x amplifications, as shown in Figure 5.16. The 
morphology of the sampled crystals was consistent throughout the run and its 
monoclinic structure is consistent with what was found by Lee et al (2006), as shown in 
Figure 5.17. This is the crystal structure currently in use for drug formulations (Florence 
and Attwood 2007). It should, however, be noticed that production of different 
crystalline forms of paracetamol and aspirin using oscillatory baffled reactors might be 
achieved by regulating different variables (e.g. temperature, used solvent, pH), as 
demonstrated in previous studies for glutamic acid (Ni and Liao 2008). 
117 
 
 
 
 
 
 
 
Figure 5.15 Literature XRD data for paracetamol (form I) (Yamamura and Momose 2003) 
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Figure 5.14 XRD data for paracetamol produced in the COBR 
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The size distributions of the paracetamol crystals along the COBR were 
determined using the particle size distribution technique and are presented in Figure 
5.18. Paracetamol crystals have a tendency to grow to large sizes and it is evident that 
the distribution was initially broader with smaller sized particles at the earlier stage of 
the crystallization and became narrower with bigger sized crystals. This shows that the 
continued mixing at a determined fixed frequency and amplitude over time has a 
selective effect on the particle size – this might be explored further in view to control 
particle size distributions to the required specifications. The Gaussian-type of size 
distribution obtained in the COBR is the direct result of the good mixing achieved 
during operation. Table 5.4 complements Figure 5.18 and shows the mean sizes as well 
Figure 5.16 SEM images of paracetamol crystals taken at different times of operation. 
a) 7.5 hrs b) 26.25 hrs c) 45 hrs d) 63.75 hrs e) 75 hrs f) 93.75 hrs 
 
Figure 5.17 Optical micrographs of monoclinic paracetamol crystals, 
in Lee et al (2006) 
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as Dv,0.1 and Dv,0.9, the sizes of particles with 10% and 90% of the samples being below 
the corresponding sizes, respectively.  The crystal size distribution results show how 
well the COBR is suited for crystallization operations and, once again, the consistency 
of the product obtained during the whole run. 
 
 
 
 
 
 
 
 
 
Figure 5.18 Particle size distribution of paracetamol samples (time of sampling = 3 hours) 
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Table 5.4 Particle size distribution for paracetamol samples 
Time of Sampling 
(hour) 
Sampling Location Mean Size 
(Dv,0.5) (µm) 
Dv,0.1 
(µm) 
Dv,0.9 
(µm) 
 
3 
 
S2 
 
185 
 
45 
 
692 
3 V4 342 95 893 
3 S3 389 125 936 
3 S4 422 141 963 
3 PV 439 146 820 
7.5 PV 451 149 824 
26.3 PV 436 143 817 
45 PV 442 151 820 
63.8 PV 448 149 826 
75 PV 433 142 816 
93.8 PV 444 153 824 
 
 
Reaction kinetics of paracetamol in the COBR was also evaluated. Samples 
were taken from different locations in the COBR and immediately quenched for HPLC 
analysis. The decrease in the concentration of 4-aminophenol along the COBR was then 
recorded and the reaction kinetics extracted as shown in Figure 5.19. Once again the 
reaction of paracetamol is of a 2nd order with a rate constant of 0.011 ml mg-1 s-1. The 
reaction times found in literature range from 5 to 12 minutes (Young 1963; Schulman et 
al 1975), which are longer than what is found in this work (circa 3 minutes) due to the 
superior mixing and heat-transfer capabilities of the oscillatory baffled reactor.  
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Figure 5.19 Kinetics of the reaction between p-aminophenol  
and acetic anhydride at 80 oC 
 
 
The COBR was again cleaned after the paracetamol experiments in COBR were 
concluded. The same cleaning procedure was used for the paracetamol run. The 
cleaning index was 33.9, which reflects the 10-fold increase in the flow rate used in the 
paracetamol production run in comparison to the aspirin production campaign, which 
allowed for a paracetamol concentration profile to be evident during the campaign. 
Figure 5.20 shows the data collected during the cleaning stage. In a similar fashion to 
what was done for the aspirin cleaning stage, a maximum allowed level of paracetamol 
in the COBR was calculated as 0.125 mg mL-1, assuming that the production would be 
reverted back to aspirin using the COBR. It is clear that the concentration of 
paracetamol that remained in the cleaning solutions was lower than that required by the 
time the cleaning was completed. The swab test () was also performed and the amount 
of paracetamol detected was also well below the maximum permitted level. The results 
show that the method used for cleaning was once more efficient. The loss of product 
due cleaning was 0.004%, lower than the industry norm of 0.1-0.2%.  The washing 
index was 4.08, which correlates to a generated waste of 8.44 L during the cleaning 
process. 
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Figure 5.20 Washing data for paracetamol 
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The kinetics of the cleaning process was evaluated and a plot of –ln(C/Co) 
versus time is shown in Figure 5.21. The first-order kinetics fits well to the 
experimental data and the mean rate constant is 0.007 s-1 for this case.  
 
This is in line with the previously obtained results and is, once again, concurrent 
with Bird’s view (1991) that the efficient mixing occurring inside the COBR during the 
cleaning stage plays a critical part in what is considered to be mainly a physical process. 
As explained in Chapter 2, it should be noted that while there are many factors that have 
an impact in the cleaning efficiency, such as the nature of the fouling substance, the 
flow rate, the cleaning temperature, the shape and nature of the cleaned surfaces or the 
nature and the concentration of the cleaning solution, establishing an explicit correlation 
between previous studies and this work is still not feasible. Table 5.5 compiles the 
kinetic data for other cleaning studies in tubular type of reactors for indication only, as 
the basis of comparison is not the same. On this standing point, the rate constants from 
this work are comparable to these from the previous studies. 
Figure 5.21 Paracetamol cleaning kinetics 
 
124 
 
Table 5.5 Comparison of cleaning data from different studies (s.s. – stainless steel) 
Authors Cleaning Solution Fouling Substance Net flow velocity (m.s-1) Temperature (0C) Cleaned surface k (s-1) 
Our data 
Tap water 
Liquinox 1% USP 
water 
vanisal sodium 0.043 
60           
room temp. 
COBR 
(glass/PFA) 
0.0045 
Our data 
Tap water 
Liquinox 1% USP 
water 
aspirin 0.064 
60           
room temp. 
COBR 
(glass/PFA) 
0.0061 
Bourne 
(1963) 
NaOH 0.03M tristearin 0.095 --- 
s.s. strip in a 
glass pipe 
0.023 
Karlsson 
(1998) 
NaOH 
0.1-0.2mg/mL 
β-lactoglobulin 0.033 24 s.s. cell 0.048 to 0.086 
Lelievre 
(2002) 
NaOH 0.5% Bacillus spores 0.2 to 3.3 60 s.s. pipe 0.0012 to 0.083 
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The ratio between the operation and the cleaning times is 427.5 for the 
paracetamol run, which shows that the cleaning stage used only a very small fraction 
(circa 0.23%) of the total operation time. As a consequence of this, the productivity is 
maximized and the operational costs are minimized. 
 
 
 
5.5 – Summary 
 
 
 The experimental results obtained for each of the chemistries selected for COBR 
work are described in this chapter. Reaction time, production campaigns and cleaning 
results are included and show that the COBR is a suitable continuous reactor for the 
synthesis of vanisal sodium, acetylsalicylic acid and paracetamol to high standards. The 
fast cleaning procedure devised for this project was effective. The reactor was cleaned 
in compliance to the stringent regulatory standards at the end of each production 
campaign.    
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CHAPTER 6  
CONCLUSIONS AND  
RECOMMENDATIONS FOR FUTURE WORK 
 
 
Just a drink, a Martini, shaken not stirred. 
James Bond, in Goldfinger (1964) 
 
 
6.1 – Conclusions 
 
 This thesis reports the first experimental research with the objective of 
establishing a cleaning protocol for fine chemicals and APIs manufactured in COBR. 
Taking this into consideration, three different chemical entities were continuously 
produced in tandem fashion, interspersed with well-defined cleaning procedures. The 
main conclusions taken from this work are subsequently summarized: 
 
• The reaction times for the studied chemistries were shorter than those described 
in literature. Some were performed under milder temperature conditions, thus 
obviating the use of reflux apparatus in the reactor. 
 
•  The crystalline forms of the produced APIs, aspirin and paracetamol, were 
consistently of the most common form I for each of the chemical entities, which 
is currently used in the pharmaceutical industry for medicine formulation 
purposes.  
 
• A precise control over the temperature profile was achieved while operating the 
COBR. In addition, particle size distribution studies revealed the uniformity of 
the crystal size obtained for the duration of the paracetamol production 
campaign.  
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• All three chemical entities were produced to high purity standards, and one of 
the main strengths of the COBR mixing technology was demonstrated by the 
presence of minimal amounts of contaminants in the fine chemical and APIs 
produced.    
 
• Products of consistent quality and yield were obtained for the duration of each of 
the production campaigns. The precise control of operational conditions in the 
COBR and the data gathered during the experiments suggests that this type of 
continuous reactor is well suited for the manufacture of high quality APIs and 
fine chemical products. 
 
• The cleaning kinetics for the studied chemical entities are of a first-order, which 
is comparable to previous work. The cleaning protocol is very simple, efficient 
and fast with a minimal amount of waste generated, in accordance to Good 
Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) standards. 
 
• The COBR design can potentially incorporate QbD principles and will play an 
important role in shaping the current pharmaceutical manufacturing industry.   
 
The data gathered and the conclusions that are taken from this work suggest that 
the COBR mixing technology is superior to current mixing technologies, not only in 
terms of the consistency demonstrated by the COBR when performing chemical 
reactions, but also in terms of crystallization and, not less importantly, the ease of 
maintenance and cleaning.  
 
The increasing trend towards process intensification and making the 
pharmaceutical industry leaner, reaching the levels of efficiency already demonstrated 
by the automotive or the semi-conductor industrial sectors is forcing the market players 
into investing more into research and development programs. Instead of expending 
large sums of money into making small improvements on already existing processes, 
the time has come for a paradigm shift, from the traditional stirred to the more efficient 
shaken.   
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6.2 – Recommendations for Future Work 
 
 
 The experimental work reported here suggests that the COBR is a better 
alternative to current mixing technologies with regards to the production of fine 
chemicals and APIs. The washing of the reactor is done with a simple, fast and effective 
cleaning procedure, thereby allowing for short turn-around times in manufacturing 
facilities.  
 
There is, however, scope for more experimentation in this field of research in 
order to better understand and optimize the processes studied. With that in mind, some 
recommendations for future work are listed below: 
 
• The intrinsic modular characteristics of the COBR design make it perfect for 
adapting more in-line and on-line process analytical technologies. Investigating 
ways of installing devices such as UV-Visible spectrophotometer or even real-
time HPLC or mass spectrometry apparatus will contribute to a better 
understanding of the phenomena occurring in the COBR, enabling a more 
informed modulation of the reaction or oscillation conditions. 
 
• Although the results obtained in the experimental work confirm the suitability of 
the COBR for performing chemical reactions and crystallization operations, 
these could be the object of further studies. Investigating how crystallization 
conditions affect both the size and crystalline structure by varying oscillation 
conditions, using different solvents or even temperature profiles could provide 
more data and help understanding these processes. 
 
• An interesting path to follow in the continuation of this research would be to 
investigate how the material that the COBR is made of interacts with how the 
processes here studied occur. In other words, replacing the glass pipes and the 
PFA baffles with a combination of materials such as stainless steel, different 
kinds of polymers or even using glass baffles could have a positive impact on 
how the chemical reactions, crystallization and cleaning processes evolve.  
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• A broader view in how the COBR interacts, complements and integrates in a 
larger, industrial manufacturing process is needed. Having a project in which 
the proven capabilities of the COBR are put to test in a real-world 
pharmaceutical or fine chemicals plant would be the definite assessment of the 
performance of this mixing technology. If successful, the publication of such 
results would help in removing the cautiousness with which new technologies 
are naturally met with by decision-makers in the industry. 
 
• A logical and critical next step in this field of research is to broaden it to other 
APIs and chemistries. This is probably the most important recommendation for 
future work, as further successes would increase the COBR’s visibility in the 
pharmaceutical and fine chemicals industries and reaffirm its place as a viable 
alternative to current mixing technologies. 
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Appendix – A 
 
cGMP Regulations and Guidelines and Compliance Actions 
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Table A.1 Applicable regulations and guidelines and compliance actions taken or to be 
taken. 
1. PREMISES AND EQUIPMENT 
 
Principle: Premises and equipment must be located, designed, constructed, adapted and maintained 
to suit the operations to be carried out. Their layout and design must aim to minimise the risk of 
errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build 
up of dust or dirt and, in general, any adverse effect on the quality of products.  
Regulations and Guidelines Measures Taken 
 
1.1 Premises should be situated in an environment 
which, when considered together with measures to 
protect the manufacture, presents minimal risk of 
causing contamination of materials or products. 
 
The equipment is located in a cleaned 
laboratory; all the chemicals used are 
labelled and stored according to suppliers 
indications. 
 
1.2 Premises should be carefully maintained, 
ensuring that repair and maintenance operations do 
not present any hazard to the quality of products. 
They should be cleaned and, where applicable, 
disinfected according to detailed written procedures. 
 
The laboratory is regularly maintained and 
properly staffed with trained personnel to 
perform maintenance and repairs. 
 
1.3 Lighting, temperature, humidity and ventilation 
should be appropriate and such that they do not 
adversely affect, directly or indirectly, either the 
medicinal products during their manufacture and 
storage, or the accurate functioning of equipment.  
 
Lightning, temperature, humidity and 
ventilation in the laboratory are adequate 
to perform the chemical reactions 
screened. 
 
1.4 Premises should be designed and equipped so as 
to afford maximum protection against the entry of 
insects or other animals. 
 
The laboratory is properly equipped for 
that effect, preventing the entry of insects 
or other animals. 
 
1.5 Steps should be taken in order to prevent the 
 
There are adequate signs in the laboratory 
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entry of unauthorised people. Production, storage and 
quality control areas should not be used as a right of 
way by personnel who do not work in them. 
entrance. The laboratory is an obligatory 
passage only to storage rooms and the 
workshop. 
 
1.6 The adequacy of the working and in-process 
storage space should permit the orderly and logical 
positioning of equipment and materials so as to 
minimise the risk of confusion between different 
medicinal products or their components, to avoid 
cross-contamination and to minimise the risk of 
omission or wrong application of any of the 
manufacturing or control steps.  
 
The working space is carefully laid-down 
taking in account this guideline, as are the 
chemical storage cupboards; the COBR 
will be positioned in such way that permits 
the reactant and product vessels to be 
inside the ventilated hood.  
 
1.7 Where starting and primary packaging materials, 
intermediate or bulk products are exposed to the 
environment, interior surfaces (walls, floors and 
ceilings) should be smooth, free from cracks and 
open joints, and should not shed particulate matter 
and should permit easy and effective cleaning and, if 
necessary, disinfection.  
 
The laboratory was built taking in account 
these considerations. 
 
1.8 Pipework, light fittings, ventilation points and 
other services should be designed and sited to avoid 
the creation of recesses which are difficult to clean. 
As far as possible, for maintenance purposes, they 
should be accessible from outside the manufacturing 
areas.  
 
The COBR will be positioned in such way 
that it will be readily accessible and 
cleaning of the premises will constitute no 
problem. 
 
1.9 Production areas should be effectively ventilated, 
with air control facilities (including temperature and, 
where necessary, humidity and filtration) appropriate 
both to the products handled, to the operations 
undertaken within them and to the external 
 
The COBR will be positioned in such way 
that permits the reactant and product 
vessels to be inside the ventilated hood. 
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environment.  
 
1.10 Production areas should be well lit, particularly 
where visual on-line controls are carried out. 
 
The laboratory is well illuminated. 
 
1.11 In-process controls may be carried out within 
the production area provided they do not carry any 
risk for the production.  
 
Temperature and pressure sensors will be 
connected to the reactor, and present no 
risk for the reactions to be carried out. 
 
1.12 Manufacturing equipment should be designed, 
located and maintained to suit its intended purpose. 
 
Careful thought was taken in the design 
and layout of the equipment to be used. 
 
1.13 Repair and maintenance operations should not 
present any hazard to the quality of the products. 
 
The COBR can be repaired/maintained off-
line to original specifications, and the 
quality of the products should not suffer 
from any quality concerns. 
 
1.14 Manufacturing equipment should be designed so 
that it can be easily and thoroughly cleaned. It should 
be cleaned according to detailed and written 
procedures and stored only in a clean and dry 
condition. 
The success of this work depends largely 
on cross-contamination control and 
elimination, and as such cleaning protocols 
will be tested and validated. 
 
1.15 Washing and cleaning equipment should be 
chosen and used in order not to be a source of 
contamination. 
 
1.16 Equipment should be installed in such a way as 
to prevent any risk of error or of contamination. 
 
1.17 Production equipment should not present any 
hazard to the products. The parts of the production 
 
Only non-reactive material such as glass, 
PFA and stainless steel will be in contact 
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equipment that come into contact with the product 
must not be reactive, additive or absorptive to such 
an extent that it will affect the quality of the product 
and thus present any hazard.  
with reactants/products. 
 
1.18 Balances and measuring equipment of an 
appropriate range and precision should be available 
for production and control operations.  
 
Balances, digital thermometers and 
pressure gauges are adequate for the 
processes to be carried out. 
 
1.19 Measuring, weighing, recording and control 
equipment should be calibrated and checked at 
defined intervals by appropriate methods. Adequate 
records of such tests should be maintained.  
 
This type of equipment is regularly 
checked, according to University 
regulations. 
 
1.20 Fixed pipework should be clearly labelled to 
indicate the contents and, where applicable, the 
direction of flow. 
 
Provisions will be taken during the 
assembly of the reactor. 
 
1.21 Defective equipment should, if possible, be 
removed from production and quality control areas, 
or at least be clearly labelled as defective. 
 
 
2. DOCUMENTATION 
Principle: Good documentation constitutes an essential part of the quality assurance system. 
Clearly written documentation prevents errors from spoken communication and permits tracing of 
batch history. Specifications, Manufacturing Formulae and instructions, procedures, and records 
must be free from errors and available in writing. The legibility of documents is of paramount 
importance.  
Regulations and Guidelines Measures Taken 
 
2.1 Formally authorised Manufacturing Formula and 
 
All the documentation produced in-house 
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Processing Instructions should exist for each product 
and batch size to be manufactured. They are often 
combined in one document. The Manufacturing 
Formula should include: 
(a) the name of the product, with a product reference 
code relating to its specification; 
(b) a description of the pharmaceutical form, strength 
of the product and batch size;  
(c) a list of all starting materials to be used, with the 
amount of each, described using the designated name 
and a reference which is unique to that material; 
mention should be made of any substance that may 
disappear in the course of processing;  
The Processing Instructions should include: 
(a) a statement of the processing location and the 
principal equipment to be used;  
(b) the methods, or reference to the methods, to be 
used for preparing the critical equipment (e.g. 
cleaning, assembling, calibrating, sterilising);  
(c) detailed stepwise processing instructions (e.g. 
checks on materials, pre-treatments, sequence for 
adding materials, mixing times, temperatures);  
(d) the instructions for any in-process controls with 
their limits;  
(e) any special precautions to be observed.  
takes in account these guidelines. 
 
2.2 There should be written procedures for sampling, 
 
The sampling procedures for the COBR 
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which include the person(s) authorised to take 
samples, the methods and equipment to be used, the 
amounts to be taken and any precautions to be 
observed to avoid contamination of the material or 
any deterioration in its quality. 
will be written taking in account these 
indications. 
 
2.3 There should be written procedures for testing 
materials and products, describing the methods and 
equipment to be used. The tests performed should be 
recorded. 
 
Product testing will be carried out in-house 
(IR, NMR, HPLC, PSD) and will be done 
in accordance to guidelines. 
 
3. PRODUCTION 
Principle: Production operations must follow clearly defined procedures; they must comply with 
the principles of Good Manufacturing Practice in order to obtain products of the requisite quality 
and be in accordance with the relevant manufacturing and marketing authorisations.  
Regulations and Guidelines Measures Taken 
 
3.1 Production should be performed and supervised 
by competent people. 
 
Appropriately trained personnel will be in 
charge of operating the equipment. 
 
3.2 All handling of materials and products, such as 
sampling, storage, (…) and processing should be 
done in accordance with written procedures or 
instructions and, where necessary, recorded. 
 
Sampling, storage and production will all 
be adequately documented. 
 
3.3 All incoming materials should be checked to 
ensure that the consignment corresponds to the order. 
Containers should be cleaned where necessary and 
labelled with the prescribed data. 
 
This is done in line with Heriot-Watt 
University practices. 
 
3.4 All materials and products should be stored under 
the appropriate conditions established by the 
 
There are adequate storage rooms and 
cupboards in order to keep chemicals well 
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manufacturer and in an orderly fashion to permit 
batch segregation and stock rotation. 
stored. 
 
3.5 Operations on different products should not be 
carried out simultaneously or consecutively in the 
same room unless there is no risk of mix-up or cross-
contamination. 
 
Special attention will be made to this, as 
success of this work depends largely on 
this and similar guidelines. 
 
3.6 At every stage of processing, products and 
materials should be protected from microbial and 
other contamination. 
 
3.7 At all times during processing, all materials, bulk 
containers, major items of equipment and where 
appropriate rooms used should be labelled or 
otherwise identified with an indication of the product 
or material being processed 
 
Provisions will be made to clearly label 
every item necessary. 
 
3.8 Labels applied to containers, equipment or 
premises should be clear, unambiguous and in an 
agreed format. 
 
3.9 Labels applied to containers, equipment or 
premises should be clear, unambiguous and in the 
company's agreed format. 
 
3.10 Any deviation from instructions or procedures 
should be avoided as far as possible. If a deviation 
occurs, it should be approved in writing by a com-
petent person. 
 
 
Provisions will be made to meet this 
guideline 
 
3.11 Access to production premises should be 
 
There are adequate signs in the laboratory 
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restricted to authorised personnel. entrance to prevent the access of 
unauthorized personnel to the premises. 
 
3.12 Contamination of a starting material or of a 
product by another material or product must be 
avoided. This risk of accidental cross-contamination 
arises from the uncontrolled release of dust, gases, 
vapours, sprays or organisms from materials and 
products in process, from residues on equipment, and 
from operators' clothing. 
 
The layout and operating procedures of the 
COBR and ancillary equipment   take in 
account this recommendation. 
 
3.13 Cross-contamination should be avoided by 
appropriate technical or organisational measures, for 
example:  
(a) providing appropriate air-locks and air extraction;  
(b) minimising the risk of contamination caused by 
recirculation or re-entry of untreated or insufficiently 
treated air;  
(d) keeping protective clothing inside areas where 
products with special risk of cross-contamination are 
processed;  
(e) using cleaning and decontamination procedures of 
known effectiveness, as ineffective cleaning of 
equipment is a common source of cross-
contamination;  
(f) using "closed systems" of production;  
(g) testing for residues and use of cleaning status 
labels on equipment. 
 
The product and reactants vessels are 
safely kept in a ventilated cupboard; 
protective clothing and safety goggles and 
gloves are kept in the laboratory at all 
times; cross-contamination avoidance and 
minimization procedures will be put in 
place when in operation. 
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3.14 Measures to prevent cross-contamination and 
their effectiveness should be checked periodically 
according to set procedures. 
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Appendix – B 
 
HPLC Chromatograms (Aspirin OBR Experiments) 
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Figure B.1 HLPC chromatogram of the synthesized acetylsalicylic acid, sample 3 
Figure B.2 HLPC chromatogram of the synthesized acetylsalicylic acid, sample 4 
Figure B.3 HLPC chromatogram of the synthesized acetylsalicylic acid, sample 5 
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Figure B.5 HLPC chromatogram of the synthesized acetylsalicylic acid, sample 7 
Figure B.6 HLPC chromatogram of the synthesized acetylsalicylic acid, sample 8 
Figure B.4 HLPC chromatogram of the synthesized acetylsalicylic acid, sample 6 
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Figure B.7 HLPC chromatogram of the synthesized acetylsalicylic acid, sample 9 
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Appendix – C 
 
HPLC Chromatograms (Paracetamol OBR Experiments) 
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Figure C.1 HLPC chromatogram of the synthesized paracetamol, sample 3 
Figure C.3 HLPC chromatogram of the synthesized paracetamol, sample 5 
Figure C.2 HLPC chromatogram of the synthesized paracetamol, sample 4 
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Figure C.5 HLPC chromatogram of the synthesized paracetamol, sample 7 
Figure C.6 HLPC chromatogram of the synthesized paracetamol, sample 8 
Figure C.4 HLPC chromatogram of the synthesized paracetamol, sample 6 
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